BioMed Research International

BioMed Research International / 2014 / Article

Review Article | Open Access

Volume 2014 |Article ID 814208 | 23 pages |

Targeted Delivery System of Nanobiomaterials in Anticancer Therapy: From Cells to Clinics

Academic Editor: Dong-Wook Han
Received25 Nov 2013
Accepted25 Dec 2013
Published19 Feb 2014


Targeted delivery systems of nanobiomaterials are necessary to be developed for the diagnosis and treatment of cancer. Nanobiomaterials can be engineered to recognize cancer-specific receptors at the cellular levels and to deliver anticancer drugs into the diseased sites. In particular, nanobiomaterial-based nanocarriers, so-called nanoplatforms, are the design of the targeted delivery systems such as liposomes, polymeric nanoparticles/micelles, nanoconjugates, norganic materials, carbon-based nanobiomaterials, and bioinspired phage system, which are based on the nanosize of 1–100 nm in diameter. In this review, the design and the application of these nanoplatforms are discussed at the cellular levels as well as in the clinics. We believe that this review can offer recent advances in the targeted delivery systems of nanobiomaterials regarding in vitro and in vivo applications and the translation of nanobiomaterials to nanomedicine in anticancer therapy.

1. Introduction

Cancer is a worldwide disease with a leading cause of mortality, accounting for about 580,350 deaths, almost 1,600 people per day in 2013 from the statistical analysis of American Cancer Society in National Cancer Institute of the US [1]. About 1,660,290 of new cancer cases are also expected to be diagnosed in 2013. The 5-year relative survival rate is still somewhat low, at 68% for all cancers diagnosed between 2002 and 2008, although it has been up from 49% in the period from 1975 to 1977. For this reason, it is essential for targeted therapy for cancer to reduce adverse reactions and mortality rate and to save costs in clinical practice. Recently, targeted anticancer therapeutics such as monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs) have been approved by the Food and Drug Administration (FDA) for the treatment of cancer [2]. The targeted therapy becomes an important element for the treatment of cancer as it helps to develop the anticancer therapeutics based on imaging and therapy (reducing the tumor size).

In this concept of targeted anticancer therapy, nanoplatforms are introduced with nanobiomaterial-based formulations or conjugation techniques in nanotechnology [3, 4]. Nanotechnology is a nanoscale-based technique in the fields of biomedical applications of pharmacology, bioengineering, biology, and medicine [5]. It currently relies on definitions provided by the National Nanotechnology Initiative (NNI) as follows [6]: (1) development of research and technology at the atomic, molecular, or macromolecular levels, within the scale of nanosize of approximately 1 to 100 nanometer in range, (2) devices and systems that have novel properties and functions based on the nanobiomaterials, because of their small and/or intermediate size, and (3) ability to control or manipulate at the atomic level. A variety of nanoparticular systems span the range from a few nanometers to hundreds of nanometers. When such nanoparticle-based systems are usually applied in solving the clinical problems, we often use the term “nanoplatforms” [7].

Nanoplatforms have been developed to manufacture nanomedicines in preclinical and clinical studies for the administration of small molecules, genes, and peptides with improvement of given in vivo behavior [810]. Figure 1 shows the schematic diagrams of targeted delivery systems with nanoplatforms, such as liposome, polymeric micelle, nanoconjugate, gold nanoparticle, carbon nanotube, dendrimer, and phage-based nanoplatform. Several characteristics of an ideal tumor-targeted nanomedicine with nanoplatforms are presented for translational research of ideal anticancer therapeutics as follows: (1) increase of drug localization into the tumor by passive targeting or active targeting, (2) decrease of drug localization in sensitive, nontargeted, and normal tissues, (3) minimal drug leakage during transit to the target, (4) prevention of degradation and premature clearance of the drug, (5) retainment of the drug at the target site during the desired period, (6) facilitation of cellular uptake and intracellular trafficking, and (7) biocompatibility and biodegradability of nanoplatforms [10]. Table 1 illustrates the recently developed nanoplatforms for cancer targeting in preclinical studies. We introduce recent studies of targeted anticancer system in the part of “recently developed nanoplatforms for cancer targeting in preclinical studies.”

NanoplatformsDrugAverage size (nm)Ligand/targetDescriptionsPossible applicationsReferences

LiposomesDoxorubicin108Cyclic Asn-Gly-Arg (cNGR) peptides/CD13 and aminopeptidase NcNGR decorated, lysolipid-containing temperature sensitive liposomesHuman fibrosarcoma (HT-1080),
in vitro binding study

Liposomes inorganic nanoparticles (gold nanorods, ironoxide nanoworms)Doxorubicin55A truncated, tumor-targeted human protein tissue factor (tTF RGD) to induce coagulation on binding to angiogenic receptors to heat specifically directed coagulation-cascade activation in tumours“Signalling” modules (PEG-decorated gold nanorods, tumor-targeted truncated tissue factor proteins) that target tumors and then locally activate the coagulation cascade to broadcast tumor location to clot-targeted “receiving” nanoparticles in circulation that carry a diagnostic or therapeutic cargo (ironoxide nanoworms, doxorubicin-loaded liposomes)In vivo MDA-MB-435 xenograft tumors,
i.v. injection

Liposomes carbon nanotubesPaclitaxel164anti-ErBb2 (Her2) mAbEach nanohorn encapsulated within one immunoliposome formulated with PEG and thermally stable and pH sensitive phospholipids for pH sensitive and prolonged release of paclitaxelSK-BR-3 and BT-20 breast cancer cells,
in vitro cytotoxicity

Polymeric nanoparticlessiRNA Cationic lipid-coated PLGA nanoparticles, a unique soft lithography particle molding process (particle replication in nonwetting templates, PRINT)In vitro prostate cancer cell lines[108]

Polymeric micelles1,2-Diaminocyclohexane- platinum(II) (DACHPt) (the parent complex of oxaliplatin)30Long-circulating, drug-loaded polymeric micelles enhancing tumour permeability with a TGF inhibitorPoorly permeable pancreatic tumors in the mice model (C26 or BxPC3 tumors),
i.v. injection

NanoconjugatesSplice-switching oligonucleotides (SSOs) (phosphorodiamidate morpholino oligomer (PMO))13RGD/integrin , a cell surface glycoprotein that is preferentially expressed
in angiogenic endothelia
Albumin-based nanoconjugates with fluorescence labeling which are small, highly specific, and noncytotoxicTumor spheroids of A375/GFP cell,
tumor spheroid study using A375/GFP cells to confirm the uptake and penetration of nanoconjugates in three-dimensional (3D) culture
Paclitaxel2-3ultrasmall hyaluronic acid (HA)/CD44Paclitaxel-ultrasmall HA (3–5 kDa) nanoconjugates internalized via CD44 receptor-mediated endocytosis, which allowed paclitaxel to bypass the P-glycoprotein- mediated efflux on the surface of cancer cellsBrain metastasis of breast cancer using MDA-MB-231Br breast cancer cells,
i.v. injection

Gold nanoparticlesChemiresistors based on functionalized gold nanoparticles in combination with pattern recognition methods5A sensor array for breath testing of exhaled breath in lung cancer patientsA noninvasive diagnostic tool for lung cancer,
in vitro array

Gold nanoparticles magnetic microparticlesAn assay for PSA detection with gold nanoparticles based on the PSA-specific Abs and short DNA sequences (barcodes)30Prostate-specific antigen (PSA)Magnetic microparticles conjugated with PSA-specific antibodies to extract trace amounts of the target analyte (PSA) in serum samples from patients and gold nanoparticles with PSA-specific antibodies and short DNA sequences (the barcodes) attached to detect this analyteAn ultrasensitive assay for prostate cancer,
in vitro barcode array

Carbon nanotube
Single-walled carbon nanotube (SWCNT) with fluorescence labelling200–300Biodistribution and examination of glomerular filtration in kidney NIR fluorescence imaging, dynamic PET imaging,
in vitro (HK-2 cells at the transwell),
in vivo (mice, NCr/nu/nu),
i.v. injection
Water soluble carbon nanotubes functionalized with PEG, radio labels, and RGD peptide1–5 (diameter), 100–300 (length)RGD/integrins RGD-pegylated SWCNTs, radio-labelled SWCNTsU87MG human glioblastoma and HT-29 human colorectal cancer cell lines, U87MG and HT-29 tumour xenograft models for biodistribution (PET),
i.v. injection

GrapheneNanographene sheet (NGS) for photothermal therapy (PTT)10–50Six-armed PEG-NGS with fluorescent labeling4T1 bearing Balb/c mice, KB and U87MG xenograft models, PTT,
i.v. injection
Reduced graphene oxide (RGO) for PTT20–80Human/murine chimeric IgG1 mAb (TRC105)/both human and murine CD105RGO conjugated to the anti-CD105 antibody TRC105Tumor vasculature targeting and imaging in living mice as a theranostic agent,
in vitro (4T1 murine breast cancer, MCF-7 human breast cancer, and human umbilical vein endothelial cells (HUVECs)),
in vivo (4T1 breast cancer model),
i.v. injection

PhageImaging and therapy HSVtk + ganciclovir + [18F]FDG and [18F]FEAU RGD4C/integrinsHybrid vector with adeno-associated virus (AAV) and fd-tet derived bacteriophage [AAV/phage (AAVP)]
RGD-4C AAVP-HSVtk (herpes simplex virus thymidine kinase)
KS1767 cells
RGD-4C AAVP-HSVtk PET images with [18F]FDG and [18F]FEAU obtained before and after ganciclovir treatment
Magnetic iron oxide [(maghemite ( -Fe2O3) or magnetite (Fe3O4)] for MRI Acidic and rich in cysteine (SPARC)SPARC-binding peptide (SPPTGIN) and triglutamate displayed on p3 and p8 coat proteins of M13 phage, respectivelyTumor targeting against prostate cancer[202]

mAb: monoclonal antibody; PEG: polyethylene glycol; PLGA: poly(lactic-co-glycolic) acid; RGD, arginine, glycine, and aspartic acid (Arg-Gly-Asp).

For successful translational research of nanoplatforms in anticancer therapy, Doxil is an FDA approved drug for the treatment of ovarian cancer, which is a long-acting pegylated liposomal formulation of doxorubicin [11, 12]. This product is based on a study of liposomal drug delivery systems for over four decades overcoming the limitations of anticancer drug and liposomes such as poor stability and reproducibility [13, 14]. It is one of the successful cases for the development of nanomedicines offering significant improvements over doxorubicin alone in clinical use. We deal with the translational research of nanomedicines in Table 2 and introduce the anticancer drugs approved by FDA in Table 3. Based on the ideal characteristics of nanoplatforms, they can be designed for the following: (1) sustained release of the drug, (2) passive accumulation of the tumor tissue, (3) ligand-based targeting of cell surface antigens or receptors with the modulation of endosomal uptake and membrane disruption, (4) drug release into the cytoplasm, and (5) protection from enzymatic degradation [15, 16]. Additionally, in this review, we demonstrate the applications of targeted delivery systems from the cells to the clinics for anticancer therapy, diagnostics, nanoimaging, bimodal imaging, and real-time intraoperative imaging.

Nanoplatforms DrugCurrent statusMode of delivery*Ligand/targetAverage size
DescriptionsTypes of cancer

Phase IIINT100–230No IRRs, high response, and reduced cardiotoxicityKaposi’s sarcoma and
metastatic breast cancer (phase I/II)
Vincristine sulfate
FDA approved (Ph-adult ALL), Phase II (NHL), Phase I (pediatric ALL)NT115Extended PKAcute lymphocytic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL)
Daunorubicin (CPX-351)
Phase IIINT100Extended PK, high responseAcute myeloid leukemia (AML)
Phase IIINT160–180Cationic liposomal formulation Various solid tumors
Phase II completedNT150Reduced myelosuppression and high responseOvarian cancer
Phase II completedNT150No IRRs and high responseMetastatic breast cancer
Phase I/IINT100Pegylated liposomal camptothecin and extended PKAdvanced solid tumors
Phase I/IITtransferrin/transferrin receptor180Extended PKAdvanced/metastatic
solid tumors
Phase I
TF(ab′)2 fragment of human mAb GAH or tumor-specific antigen140No hand-foot syndrome or cardiotoxicityMetastatic stomach cancer
p53 gene
Phase IbTscFv/transferrin receptor90Improved responseSolid tumors
RB94 plasmid DNA (SGT-94)Phase ITscFv/transferrin receptor108Improved responseSolid tumors
Phase ITscFv/ErbB2 (HER2)75–110Advanced breast cancer
Melanoma antigens and IFNγ (Lipovaxin-MM)Phase ITSingle domain antibody (dAb) fragment (VH)/DC-SIGNStable and safeMelanoma vaccine

Approved (Korea); phase II/III (USA)NT<50Polymeric micelles, increased paclitaxel MTD, high responseMetastatic breast cancer and urothelial carcinoma
Phase IIINT85Core-shell-type polymeric micelles, extended PK, high response, and reduced hypersensitivity Metastatic/recurrent breast cancer

PolymersDoxorubicin (SP1049C)Phase I completedNT30Polymeric micelles,
high response, and no hand-foot syndrome
Advanced adenocarcinoma of esophagus and gastroesophageal system
Phase II (Asia)NT40Polymeric micelles,
extended PK
Metastatic/recurrent solid tumors
Phase IIINT10–150Polymeric micelles, extended PKOvarian cancer
Campthotecin (CRLX101)Phase Ib/IIaNT20–50A pH-sensitive polymer nanocarrier releasing camptothecin in the acidic environment of cancer cells, extended PK, and high responseAdvanced solid tumors
(SN-38, NK012)
Phase I/IINT20Polymeric micelle-based active metabolites of camptothecin derivative and extended PKSolid tumors
(NC-6004, Nanoplatin)
Phase I/II (Asia)NT30Polymeric micelles and extended PK (with the aim of reducing kidney toxicity compared with cisplatin alone)Advanced/metastatic pancreatic cancer (evaluating nanoplatin in combination with gemcitabine in patients with advanced or metastatic pancreatic cancer)
Phase I completedTPeptide/PSMA
(solid or metastatic prostate cancer cells by binding to prostate-specific membrane antigen)
100Enhanced therapeutic efficacy and partial responseSolid tumors
RRM2 siRNA (CALAA-01)Phase ITTransferrin/transferrin receptor70Cyclodextrin-based nanoparticle containing anti-RRM2 siRNA and no DLTsSolid tumors

PK: pharmacokinetics; DRR: drug release rate; IRRs: infusion-related reactions; Ph-: Philadelphia Chromosome Negative; MTD: maximum tolerable dose; DLTs: dose-limiting toxicities; DC: dendritic cell.
*Mode of delivery: NT: nontargeted (passive targeting), T: targeted (active targeting).

NanoplatformsDrugCompanyPropertiesIndicationsRoutes of administration

LiposomesAbelcetEnzonLiposomal amphotericin BFungal infectionsi.v.
AmBisomeGilead SciencesLiposomal amphotericin BFungal and protozoal infectionsi.v.
AmphotecThree Rivers PharmaceuticalsCholesteryl sulfate-based amphotericin BFungal infectionsi.v.
DepoCytSkyePharmaLiposomal cytarabineMalignant lymphomatous meningitisi.t.
DaunoXomeGilead SciencesLiposomal daunorubicinHIV-related Kaposi’s sarcomai.v.
Doxil/CaelyxOrtho Biotech,
Liposome-PEG doxorubicinHIV-related Kaposi’s sarcoma, metastatic
breast cancer, and metastatic ovarian cancer
MyocetZeneusLiposomal doxorubicinCombination therapy with
cyclophosphamide in metastatic
breast cancer
VisudyneQLT, NovartisLiposomal verteporfinPhotodynamic therapy (PDT) for age-related macular degeneration, pathologic myopia, and ocular histoplasmosisi.v.

PolymersAdagenEnzonPEG-adenosine deaminaseSevere combined immunodeficiency
disease associated with ADA deficiency
CopaxoneTEVA PharmaceuticalsL-Glutamic acid, L-alanine,
L-lysine, and L-tyrosine copolymer
Multiple sclerosiss.c.
Genexol-PMSamyangMethoxy-PEG-poly(D, L-lactide) paclitaxelMetastatic breast canceri.v.
MacugenOSI PharmaceuticalsPEG-anti-VEGF aptamerAge-related macular degeneration i.r.
NeulastaAmgenPEG-GCSFNeutropenia associated with cancer
OncasparEnzonPegaspargase (PEG-L-asparaginase)Acute lymphoblastic leukemiai.v., i.m.
RenagelGenzymePoly(allylamine hydrochloride)End-stage renal diseaseOral
SomavertNektar, PfizerPEG-HGFAcromegalys.c.

OthersAbraxaneAbraxis BioScience,
Albumin-bound paclitaxelMetastatic breast canceri.v.
EstrasorbNovavaxEstradiol emulsionVasomotot symptoms associated with menopauseTopical and transdermal
EmendElan, MerckNanocrystalline aprepitantAntiemeticOral
Megace ESStrativa Pharmaceuticals, subsidiary of Par
Pharmaceutical. Inc.
Nanocrystalline megestrol acetateAnorexia, cachexia, or an unexplained significant weight loss in AIDS patientsOral
RapamuneElan, Wyeth
Nanocrystalline sirolimusImmunosuppressantOral
TriCorElan, AbbottNanocrystalline fenofibrateAntihyperlipidemicOral
FeridexBayer Healthcare Pharmaceuticals Femmoxides solution (superparamagnetic iron oxide)MRI contrast agenti.v.

ADA: adenosine deaminase; GCSF: granulocyte colony-stimulating factor; HGF: hepatocyte growth factor; HIV: human immunodeficiency virus; i.m.: intramuscular; i.r.: intravitreous; i.t.: intrathecal; i.v.: intravenous; PEG: polyethyleneglycol; s.c.: subcutaneous; VEGF: vascular endothelial growth factor.

2. Mechanism of Cancer Targeting by Nanoplatforms

Many nanobiomaterial-based platforms have been designed and evaluated for drug targeting to cancers as shown in Figure 2. Most of these platforms are “passive targeting” concepts to improve the circulation time of the conjugated or encapsulated therapeutic drug such as liposomes, polymers, micelles, and nanoparticles. Solid tumors have blood vessels with enhanced vascular permeability and a lack of functional lymphatics, which allow extravasation of carrier materials with sizes of up to several hundreds of nanometers and are unable to eliminate extravasated nanomaterials. From the several reports, this EPR effect was shown even for the particles size of 1-2 μm (e.g., Lactobacillus sp., Salmonella sp., etc.), which could make the particles accumulated in tumor tissues [17, 18]. Therefore, long-circulating nanomedicines are able to be accumulated in tumors over time based on a mechanism known as the enhanced permeability and retention (EPR) effect [19, 20]. The EPR effect is a unique phenomenon of solid tumors related to their anatomical and pathophysiological differences from normal tissues and is the most important strategy to improve the delivery of therapeutic agents to tumors for anticancer drug development. Examples of passively targeted nanoplatforms approved for clinical use are Doxil (Caelyx in Europe; pegylated liposomal doxorubicin), DaunoXome (nonpegylated liposomal daunorubicin), DepoCyt (nonpegylated liposomal cytarabine), Myocet (nonpegylated liposomal doxorubicin), Oncaspar (pegylated L-asparaginase), Abraxane (albumin-based paclitaxel), and Genexol-PM (paclitaxel-containing polymeric micelles, approved in Korea). In particular Doxil is a pegylated liposome-based, doxorubicin-loaded anticancer drug, which is FDA approved for the treatment of ovarian cancer as mentioned above. This drug has a severe cardiotoxicity although it overcomes poor stability and reproducibility of liposomes and improves a biodistribution of doxorubicin in tumor tissues by EPR effect. In addition, Abraxane is a Cremophor EL-free albumin-bound paclitaxel. It reduced Cremophor EL-associated side effects of Taxol such as severe anaphylactoid hypersensitivity reactions, hyperlipidaemia, abnormal lipoprotein patterns, aggregation of erythrocytes, and peripheral neuropathy [21]. Next-generation nanomedicines for anticancer therapy are developing alternative approaches with recently developed nanoplatforms minimizing side effects of surfactants in formulations and targeting tumor tissues. Several additional passively tumor-targeted nanomedicines are currently in clinical trials (Table 2), and many other ones are in early and late-stage preclinical development [9, 2225].

On the other hand, “active targeting” strategy indicates the use of targeting ligands like antibodies and peptides which are attached to drugs and drug delivery nanoplatforms for binding to receptor expressed at the target site. In this strategy, active targeting systems with ligands and antibodies need to be accumulated first in tumor tissues by EPR effect, and then active targeting could be achieved. Targeting ligands for actively targeting nanomedicines are improving cellular internalization via endocytosis-prone surface receptors, such as folate [26], galactosamine [27], EGF [28], and transferrin [29]. To date, targeting techniques for active targeting are advanced at the preclinical level, however, only antibody-based nanomedicines have been approved for clinical use (Tables 2 and 3). Zevalin (CD20-targeted 90Yttrium-ibritumomab tiuxetan), Bexxar (CD20-targeted iodine-131 tositumomab), Ontak (CD25-targeted diphtheria toxin-IL-2 fusion protein), and Mylotarg (CD33-targetd gemtuzumab oxogamicin) have been successfully used for non-Hodgkin’s lymphoma, T-cell lymphoma, and acute myeloid leukemia. In addition, it has necessitated the use of peptides to enable the cell internalization of cancer drugs such as cell-penetrating peptides, protein-transduction domains, oligoarginine, and TAT [30].

Active targeting to receptors, which are overexpressed by angiogenic endothelial cells, can reduce blood supply to tumors that deprive the tumor cells from oxygen and nutrients in solid tumors. Ligands used for drugs and drug delivery platforms to tumor vasculature include antibody fragment L19 [31], as well as several cyclic and linear derivatives of the oligopeptide RGD and NGR, which bind to angiogenic endothelium through the integrins (, , and ) and aminopeptidase-N (CD13), respectively [32, 33].

Although active targeting systems are extensively studied to develop anticancer therapeutics, there has been a less example of clinical use compared to passive targeting systems. Discussing these problems to overcome, active targeted nanoplatforms are physicochemically unstable for blood circulation in the body and hard to be accumulated in tumor tissues due to their size of conjugated targeting ligands of formulations (e.g., monoclonal antibodies) [34]. In addition, active targeting systems can be eliminated by nanoparticular surface opsonization (nonspecific protein adsorption) and nanoparticular uptake and retention to reticuloendothelial systems resulting in poor efficiency of active targeting system in vivo [35]. Based on these fundamental problems and technical barriers, multifunctionality, targetability, and stability are necessary to overcome the low efficiency of active targeting nanoplatforms.

3. Nanoplatforms of Anticancer Therapeutics and Application in Clinical Trials

Targeted delivery systems of nanobiomaterials are currently in the process of developing nanoscale-sized platforms or surface modification of nanoplatforms with active targeting ligands that support multifunctionality due to poor solubility of anticancer drugs or toxic effect of drugs on noncancerous cells and tissues [36, 37]. Most of the anticancer drugs are poorly soluble or insoluble in water. Thus, organic solvents or toxic surfactants are usually applied for the formulation of anticancer therapeutics even used in clinics. In addition, anticancer drug alone has a toxic effect on normal cells and tissues without target specificity [38, 39]. Therefore, several nanoplatforms in 100 nm diameter based on nanobiomaterials have been used to administer the anticancer drugs to minimize the adverse toxicity and to maximize the drug effect within the therapeutic index [40].

Nanoplatforms offer solubility of poorly soluble anticancer drugs in water preparing soluble suspensions with the minimum need for organic solvents and surfactants which cause toxicity [40, 41]. These platforms are accumulated in the tumor tissues by the EPR effect, as mentioned above. The nanoplatforms are also used in the targeted delivery systems of active targeting using the decoration with receptor-targeted ligands or tumor antigen sensitive antibodies together with anticancer drugs [22, 37, 4244]. The anticancer drugs encapsulated into the nanoplatforms, specifically liposomal nanoplatforms and polymer-based nanoplatforms, are undergoing clinical trials [43, 45, 46]. Table 2 shows the nanomedicines of anticancer drugs in clinical trials.

3.1. Doxorubicin

Doxorubicin, a very effective anticancer drug, is widely used in the treatment of breast, ovarian, bladder, and lung cancers [47]. Mechanism of action of doxorubicin is the blocker of topoisomerase II, which is an important enzyme in the DNA replication process that unwinds the DNA helix. The mechanisms of doxorubicin also include DNA cross-link and ROS generation besides inhibiting topoisomerase II. Based on these mechanisms of action, doxorubicin has a potent antitumor activity in tumor cells inducing cell death. However, doxorubicin is associated with the severe side effects on the heart including irreversible myocardiotoxicity and fatal congestive heart failure [48]. To decrease the toxicity of doxorubicin, nanoplatforms were introduced to enhance pharmacokinetic parameters with an accumulation of drugs in the tumor tissues, thereby minimizing the cardiotoxicity. Liposomes and polymeric nanoplatforms were studied and developed as nanomedicines via an intravenous route. Myocet, MCC-465, MM-302, SP1049C, and NK911 are the liposomal or polymeric nanopaltforms of doxorubicin in the clinical trials [49]. Myocet, MCC-465, and MM-302 are based on the liposomal nanoplatforms at the range of 100–140 nm in diameter [50]. In the cases of MCC-465 and MM-302, the target-specific ligands of F fragment in human mAb GAH or tumor-specific antigen and scFv/ErbB2 (HER2) are incorporated into the liposomal nanoplatforms, respectively. In other words, SP1049C and NK911 are used in the polymeric micelles. SP1049C is a Pluronic-based micellar formulation of doxorubicin [51] and NK911 is a core-shell-type polymeric micellar nanoplatform of doxorubicin which consists of a block copolymer of PEG (m.w., 5000) and poly(aspartic acid) (30 units) conjugated with doxorubicin [52]. Doxorubicin is entrapped into the highly hydrophobic inner core of the polymeric micellar nanoplatforms.

3.2. Paclitaxel

Paclitaxel is a chemotherapeutic agent for the ovarian, breast, and lung cancers as well as Kaposi’s sarcoma [53]. It is a mitotic inhibitor with a stabilizing activity of the microtubule assembly interfering the normal breakdown of microtubules during cell division. Paclitaxel was originally extracted from the Pacific yew tree, Taxus brevifolia. Bristol-Myers Squibb commercially developed paclitaxel, a famous trademark, Taxol. However, paclitaxel itself has severe adverse responses such as peripheral sensory neuropathy [54, 55], anaphylaxis, and hypersensitivity reactions due to its solubilizing materials (Cremophor EL and ethanol) [55]. Therefore, the development of nanoplatforms is essential to overcome these problems of formulation for the improvement of pharmacokinetic parameters and the toxic adverse reactions in the normal tissues [56]. EndoTAG-1 [57], LEP-ETU [58], Genexol-PM [59], NK105 [60], and Opaxio [61] are developed as paclitaxel-loaded nanoplatforms undergoing clinical trials. EndoTAG-1 and LEP-ETU are based on the liposomal nanoplatforms. In particular, EndoTAG-1 is based on the cationic liposomal formulation, which can interact with the newly developed and negatively charged endothelial cells in the disease states for the growth of tumor blood vessels targeting the blood supply to the tumor cells [57]. Polymeric nanoplatform-based paclitaxel formulations are also developed such as Genexol-PM, NK105, and Opaxio. Paclitaxel is conjugated to poly(l-glutamic acid) (PGA) in Opaxio [61], monomethoxy poly(ethylene glycol)-block-poly(D,L-lactide) (mPEG-PDLL) in Genexol-PM [59], and NK105 polymers of PEG as the hydrophilic segment and modified polyaspartate as the hydrophobic segment in NK105 [62], respectively.

3.3. Platinum-Based Anticancer Drugs

Cisplatin (cisplatinum or cis-diamminedichloroplatinum (II)) is also used in chemotherapy, which is a platinum-based anticancer drug for the treatment of various cancers including sarcomas, some carcinomas (e.g., small cell lung cancer and ovarian cancer), lymphomas, and germ cell tumors [63, 64]. Mechanism of action in platinum-based anticancer drug is DNA cross-linking to interfere with the cell division by mitosis triggering apoptosis or cell death. Oxaliplatin and carboplatin are also included in platinum-based anticancer therapeutics. In clinical trials, oxaliplatin (MBP-426) [65] and cisplatin (NC-6004, Nanoplatin) [66] are studied for their applicability to advanced/metastatic solid tumors. In particular, Nanoplatin in combination with gemcitabine is evaluated for the treatment of advanced/metastatic pancreatic cancers. MBP-426 is reported as an oxaliplatin-based liposomal nanoformulation with the surface modification of transferrin targeting transferrin receptors in disease states. In the case of polymeric nanoplatforms, Nanoplatin, a polymeric micelle-based cisplatin of 30 nm in diameter, is studied for its kidney toxicity reduction capabilities compared to cisplatin alone.

3.4. Camptothecins

Camptothecin and irinotecan, a water-soluble derivative of camptothecin, are cytotoxic alkaloids isolated from Camptotheca acuminate [67]. The target of these camptothecins and their derivatives is topoisomerase I to inhibit the replication in the cells. They bind to the topoisomerase I and DNA complex generating a stabilized ternary complex to prevent DNA religation and to cause DNA damage resulting in apoptosis. Camptothecin and its derivative are limitedly used due to lipophilicity and instability of the lactone ring structure by hydrolysis despite their superior anticancer activity [68]. Therefore, the nanoplatform-based camptothecin (S-CKD-602 [69] and CRLX101 [70]) and irinotecan (SN-38, NK012 [71]) are developed undergoing clinical trials. S-CKD-602 and CRLX101 are used in the nanoplatforms of a pegylated liposome and a polymeric micelle, respectively. In the case of irinotecan (SN-38, NK012), it is a polymeric micelle-based active metabolite of camptothecin to exploit the EPR effect in the diameter size of 20 nm. This system is constructed in an amphiphilic block copolymer, PEG-PGlu (SN-38), by the self-assembly in the aqueous media. NK012 had an antitumor activity with tolerance that included partial responses and several occurrences of prolonged stable disease across a variety of advanced refractory cancers in the clinical studies.

3.5. Gene Therapy

Plasmid DNA and siRNA for cancer gene therapy are also used for the treatment of cancers in the clinical trials. The aim of gene therapy is to kill the cancer cells blocking the transduction of the tumor cells or inhibiting the disease-induced proteins without any damage to the normal cells, using cancer-specific genetic materials [72]. For the current clinical trials, p53 gene (SGT53-01) [73], RB94 plasmid DNA (SGT-94) [74], and RRM2 siRNA (CALAA-01) [75] are studied for the treatment of solid tumors. These materials are based on tumor-specific nanoplatforms, which are the liposomal (SGT53-01 and SGT-94) or cyclodextrin-based nanoparticular (CALAA-01) systems decorated with a target ligand of transferrin receptors in the tumor cells. These nanoplatforms are necessary in delivering the genetic materials into the tumor cells due to the instability in the biological fluids (e.g., enzymatic digestion) and the hydrophilicity of genetic materials (e.g., poor uptake to cells).

4. Recently Developed Nanoplatforms for Cancer Targeting in Preclinical Studies

4.1. Liposomes

Liposomes have been developed as bioinspired nanoplatforms, which define the phospholipid bilayer showing the properties of the cell membrane [76, 77]. The liposomal nanoplatform can carry the hydrophilic drug at the aqueous core inside the bilayer and the hydrophobic drug at the lipid membrane. This nanoplatform has a lot of advantages for the delivery system with a great attention given their biocompatibility and targetability from the in vitro characterization to translational research [50, 78, 79]. For cancer targeting, liposomes are extensively used as passive targeting agents and ligand-mediated or stimuli-sensitive targeting agents (active targeting agents) [80]. Based on their biocompatibility, liposomes have been early developed as nanoplatforms to transfer small molecules in the tumor tissues [14]. Various anticancer drugs such as doxorubicin, doxorubicin derivatives, paclitaxel, and platinum-based anticancer drugs are usually loaded into the liposomal platforms (Table 1). These are 100–200 nm in average size, which makes liposomes take a trip into the tumor tissues.

Liposomes can also be used in the targeted delivery system with several modification of the liposomal surface design [8184]. Cancer targeting systems are rapidly used in broad applications for the tumor-specific ligands [85, 86] or tumor-associated antigens [87] although liposomes are possible to be used in anticancer therapy as the delivery carriers for passive cancer targeting. The cancer-targeted therapy with targeting ligands includes leukocyte differentiation antigen (CD33) for acute myeloid leukemia [88], GD2 for neuroblastoma [89], and the folate receptor for wide human tumors [90, 91]. In addition, integrins [92], vascular endothelial growth factor receptors (VEGFR) [93], and CD13/aminopeptidase N [94] are also used as the targeting ligands. Liposomes with cyclic Asn-Gly-Arg (cNGR) peptide targeted to CD13 were currently formulated with lysogenic lipids-loaded doxorubicin for the potential treatment of human fibrosarcoma [95]. These systems are not only ligand-targeted systems for cancer metastasis, but also the hyperthermia-targeted systems for tumor hyperthermia, which regulates the release of doxorubicin specifically in the hyperthermal tissues for cancer targeting.

Liposomes can also be used as one of the components in the nanohybrid systems [96]. A study by Von Maltzahn et al. reported a complexed nanohybrid system for the treatment of human breast cancer in the xenograft tumor model of MDA-MB-435 cells [97]. This system is the complex of “signaling modules” to activate and broadcast the tumor location and “receiving modules” to carry the nanoplatform-based diagnostic agents and therapeutic drugs. They used the doxorubicin-loaded liposomes as therapeutic cargos with iron oxide nanoworms as the diagnostic agents in circulation. In addition, for the activation of doxorubicin-loaded liposomal cargos, PEG-decorated gold nanorods and tumor-targeted truncated tissue factor proteins (tTF-RGD) were previously introduced as the signaling modules to induce the heat specifically directed coagulation on binding to the angiogenic receptors in tumors before adding the doxorubicin-loaded liposomes. This system can be applied for the targeted theranostic agents to detect and treat the tumors together. Liposomes can also be used together with carbon nanotubes [98, 99]. Huang et al. reported carbon nanotubes encapsulated into the liposomes, which carried paclitaxel and anti-ErBb2 (Her2) mAb for this system SK-BR-3 and BT-20 breast cancer cells and checked the in vitro cytotoxicity [98]. This system can also be applied to theranostics for the potentiality of diagnostics and therapeutics.

4.2. Polymeric Nanoparticles/Micelles

Polymers are innovative nanobiomaterials to be engineered for the delivery system of drugs, genes, and peptides [41, 100]. Polymeric nanoparticles or micelles are easily prepared to be nanosized with various designs, which are relatively smaller in size compared to lipid-based formulations that generally range in size of 1–50 nm. Polymers can be used to carry multiple ligands for cancer targeting and imaging molecules for cancer diagnostics with a simple conjugation-based structural modification [101]. Among the polymers, PEG and poly(lactic-co-glycolic) acid (PLGA) are extensively used as biocompatible polymers for translational medicine [102, 103].

PLGA is one of the most widely used polymers due to its biocompatibility, which is degraded to the monomers of lactic acid and glycolic acid in the body [104]. PLGA was approved by US FDA and European Medicine Agency (EMA). PLGA-based nanoparticles are successfully applied for drug delivery of the biomedical approaches for the development of translational medicine [105]. For example, paclitaxel-encapsulated PLGA nanoparticles were formulated with a strong enhancement of the cytotoxic effect of paclitaxel on the tumor cells in vitro and in vivo compared to commercial formulation, Taxol [106, 107]. Hasan et al. published the cationic lipid-coated PLGA nanoparticles with a unique soft lithography particle molding process, which was applied for the delivery of siRNA in the prostate cancer cells [108]. In this study, they coated the PLGA nanoparticles with cationic lipid for a successful internalization to the cells based on a charge-charge interaction of the cell membrane and nanoparticles because PLGA has a negative charge. Based on the addition of targeting ligands like cLABL (ICAM-1 targeting) [109], folate (folate receptor) [110, 111], prostate-specific receptor antigen (prostate-specific receptor targeting) [112, 113], RGD (integrins ) [114, 115], and AS1411 (nucleolin targeting) [116, 117], PLGA nanoparticles have the potential to improve drug efficacy via target specificity of nanoplatforms in vitro and in vivo.

Although these nanoparticles have an effective function in cancer therapy in preclinical trials, these nanoparticles can be removed in circulation based on the biological barrier and reticuloendothelial system (RES), which performs an opsonization to macrophages that are internalized by phagocytosis [118]. PEG is the most commonly used polymeric moiety for the surface modification of nanoplatforms [119]. Nanoparticles can be usually decorated with targeting ligands conjugated with PEG. PEG originally has a function to make nanoparticles sterically stable for the prolonged circulation in the blood after administration. This method is called “pegylation” [120]. It demonstrates the hydrophilic moiety of PEG on the particular surface in the nanoplatforms, which provides the steric hindrance of a particular system to be shielded against the RES system for a prolonged delivery of the drug. Aravind et al. studied the long-circulating, drug-loaded polymeric micelles enhancing tumor permeability with a TGFβ inhibitor in the poorly permeable pancreatic tumors in a murine model of the C26 or BxPC3 tumors [116]. They loaded 1,2-diaminocyclohexane-platinum(II)(DACHPt), which is the parent complex of oxaliplatin, in the polymeric micelles of PEG-b-poly(glutamic acid) (PEG-b-P(Glu)) copolymer and P(Glu) homopolymer. After the size-based screening of permeability into the tumors, 30 nm sized micelles had a relatively enhanced tumor permeability, when transforming growth factor was administrated together with the micelles.

4.3. Nanoconjugates

Nanoconjugates have extensively been studied as the smart nanoplatforms with active functional groups to prepare the covalent binding for the anticancer therapeutics [121]. Polymeric nanoconjugates are generally synthesized with a simple conjugation of the functional groups in the polymer such as –OH, –COOH, and –NH2. These steps are stepwise reactions, which need to avoid uncontrollable side chemical synthesis. Nanoconjugates include the nanoplatforms of polymeric nanoparticles/micelles and other nanoparticles based on the characteristics of conjugation technique to prepare the nanoconjugate platforms using the functional groups of nanobiomaterials. Polymer-drug conjugates [122, 123] or mAb conjugates [42] were reported for targeted anticancer therapy. Xiong et al. introduced the cisplatin-based poly(γ, l-glutamic acid)-citric acid-based nanoconjugates [123], and Segal and Satchi-Fainaro illustrated the polymeric nanoconjugate-based therapeutics with favorable polymers such as N-(2-hydroxypropyl)methacrylamide (HPMA), polyglutamic acid (PGA), and β-poly(L-malic acid) (Polycefin) [122]. In addition, Julien et al. showed mAb-targeted nanobiomaterials for anticancer therapy [42]. They described the mAb-drug conjugates with an introduction of mAb-based therapeutics such as CD20 (Rituxan for B-cell lymphoma), HER2 (Herceptin for breast cancer), VEGF (Avastin for colon, lung, breast, and renal cancer), and EGFR (Erbitux for colon and lung cancer).

These platforms have more advantages than other nanoplatforms, like micelles and liposomes, in the way that they are small in size and chemically stable in biological fluid. For this reason, these platforms are easily applied to the functionalization of multiple-target ligands or theranostic agents with polymers, peptides, proteins, or other nanoparticles. For example, folate is a widely used ligand for cancer targeting, which can have an interaction with the overexpressed folate receptors in cancer states [124]. Folate receptors are highly overexpressed in epithelial, ovarian, cervical, breast, lung, kidney, colorectal, and brain tumors while they are restrictedly expressed in the normal tissues, such as the lung, kidney, placenta, and choroid plexus, which are limited to the apical surface of the polarized epithelia [124, 125]. Folate has a lot of advantages to be used for a targeting ligand through the conjugation to nanobiomaterials based on its small molecular weight (441 Da) and the easy preparation method of folate-linked nanobiomaterials due to the stability of folate over a broad range of temperatures and pH values [126]. Zwicke et al. focused on the folate-based nanoconjugates for anticancer therapy with doxorubicin or paclitaxel and cancer imaging with other contrast agents like gold nanoparticles, iron oxide nanoparticles, or carbon nanotubes [127].

The nanoconjugate systems can be the effective targeting nanoplatforms of macromolecules to the tumor tissues based on their ultrasmall size although they carried the ligand-based targeting systems of cell surface antigens, peptides, or polymers. The albumin-based nanoconjugates were introduced by Ming et al. [128], which carried phosphorodiamidate morpholino oligomer (PMO) type splice-switching oligonucleotides (SSOs) with a RGD peptide for integrin , a cell surface glycoprotein, as an active targeting ligand and a fluorescence label. This system was very small based on 13 nm of size. It had a high specificity without cytotoxicity. In particular, it was applied to the tumor spheroids of A375 cells to check the uptake and penetration of the albumin-based nanoconjugates into the three-dimensional (3D) cultures. In addition, these nanoconjugates can overcome the drawbacks of conventional chemotherapy such as drug toxicity to normal cells and cancer drug resistance by specific targeting and activating the cancer cells via the multiple decorations of target ligands on the nanoconjugates. Mittapalli et al. also reported the paclitaxel-ultrasmall hyaluronic acid (HA) nanoconjugates [129], which is a CD44 receptor targeting system for the treatment of brain metastasis of breast cancer in a model of MDA-MB-231 breast cancer cells. They used an ultrasmall HA (3–5 kDa) as a target ligand to interact with CD44 receptors on the surface of the cancer cells. In addition, this ultrasmall HA-mediated cellular uptake of paclitaxel avoided the P-glycoprotein-mediated efflux showing the drug resistance in cancer cells. In particular, this system exhibited a small size of 2-3 nm, like a single molecule of the nanoconjugates, and can self-assemble into larger particles.

4.4. Inorganic Nanoparticles—Iron Oxide Nanoparticles, Superparamagnetic Iron Oxide Nanoparticles, and Gold Nanoparticles

Inorganic nanoparticles have been currently investigated as contrast agents in clinical practice [130]. Iron oxide nanoparticles and superparamagnetic iron oxide nanoparticles have been studied extensively as contrast agents because they enhance the negative contrasts and give us darker images of the interest regions in magnetic resonance imaging (MRI). Iron oxide nanoparticles have a magnetic moment to be changed by an ambient thermal energy. This system has been widely used for MRI contrast enhancements, as well as tissue-specific release of therapeutic agents [131]. Superparamagnetic iron oxide (SPIO) nanoparticles are either form which includes the inside of the core of magnetic nanoparticles with a polymeric coating or a homogeneous integration into the polymeric nanoparticles [4]. This nanoparticular system has a small size with the range of 3–6 nm of the core size and 20–150 nm after dextran coating such as Feridex and Combidex, which is a superior biocompatible magnetic material-based biomedical technique with respect to other magnetic materials, both based on oxides or pure metals [132]. In addition, this system can deliver anticancer drugs such as doxorubicin and methotrexate, which is used as theranostic cargo system due to its small size [133, 134]. In addition, the gold nanoparticles were used together with the iron oxide nanoparticles to study the MRI contrast agents, as well as the optical probes exploiting the reflectance signal of the gold nanoparticles [135].

The gold nanoparticles can also be used in an ultrasensitive assay technique to detect cancers [136]. Peng et al. introduced the functionalized gold nanoparticles in combination with the pattern recognition methods to diagnose the lung cancer from breath testing [137]. This method is an in vitro sensor array technique of the detection of biomarkers in exhaled breath of lung cancer patients as a noninvasive diagnostic tool. In addition, Thaxton et al. reported the combination system based on the magnetic microparticles and the gold nanoparticles conjugated with the prostate-specific antigen- (PSA-) specific antibodies to diagnose prostate cancers [138]. In this system, the magnetic microparticles conjugated with PSA-specific antibodies were used to extract the traceable amounts of PSA in the serum samples from patients, and the gold nanoparticles with PSA-specific antibodies and short DNA sequences (the barcodes) were attached to detect this analyte for in vitro barcode assay.

4.5. Carbon-Based Nanoplatforms—Carbon Nanotubes and Graphene

Graphite is one of the carbon-based natural materials that are widely used in large-scale industrial applications such as steelmaking and battery electrodes [139]. From graphite, carbon-based nanobiomaterials have been engineered with the deeper nanofabrication techniques, which include carbon nanotubes and graphene [140]. These nanobiomaterials are currently and widely regarded as highly attractive biomedical application systems that have a multifunctional nature. In addition, they are incorporated into the conventional existing nanobiomaterials, so-called the hybrid system with further function [141, 142].

Carbon nanotubes are cylindrical nanostructure-based carbon materials, which are synthesized by an arc discharge or chemical vapor deposition of graphite [143]. They are shaped like rolling sheets of carbon into the hollow tubes. Their sizes are ultrasmall, 0.4 to 2 nm in diameter of single-walled carbon nanotubes (SWCNTs) [144, 145]. This system can also be modified to be suitable for biological applications with an addition of functional groups, targeting molecules, and polymers, and so forth to enhance the solubility and biocompatibility [146]. Ruggiero et al. studied the biodistribution and glomerular filtration in the kidney of SWCNT with fluorescence label. This system was applied to the near infrared (NIR) fluorescence imaging and dynamic positron emission tomography (PET) imaging [147]. For the enhancement of solubility of the carbon nanotubes, Liu et al. reported the water soluble carbon nanotubes functionalized with PEG [148]. In addition, this water soluble carbon nanotube system with radio labels and RGD peptide targeted integrins for the treatment of human glioblastoma and human colorectal cancer in the U87MG and HT-29 tumor xenograft models. They checked the biodistribution of this system using PET scan in the murine tumor model after intravenous injection.

Graphene is a single planar sheet structured carbon-based material, which is a single atomic plane of graphite, in a honey comb crystal lattice [149]. It is isolated by a simple method for extracting graphene from graphite via exfoliation [150]. Graphene is similar to carbon nanotubes in that it has similar electrical, optical, and thermal properties, although the structure of graphene is two-dimensional atomic sheet different from carbon nanotubes [151]. Graphene can be an attractive material since it has the possibility of being engineered to be structurally thin and flexible. For the biomedical applications, graphene oxide and reduced graphene oxide are more commonly used due to its solubility in aqueous environments and capability of chemical functionalization [152]. Graphene oxide was produced by the oxidation of graphite under acidic conditions (e.g., the modified Hummer’s method), and reduced graphene oxide was provided from a reduction of graphene oxide with several reducing reagents (e.g., hydrazine) [153]. They are applied to the biomedical nanomedicine including injectable drug delivery systems for anticancer therapy as carbon nanotubes [154]. For example, the nanographene sheet (NGS) for photothermal therapy (PTT) was reported by Shi et al. [155], which was a six-armed PEG-NGS of 10–50 nm in size with fluorescence labeling for PTT of cancers in the models of 4T1 bearing Balb/c mice, as well as KB and U87MG xenograft models after intravenous injection. In addition, reduced graphene oxide was applied to PTT in tumor models by Yang et al. [156] who used the reduced graphene oxide conjugated with the chimeric form of anti-CD105 mAb, TRC 105, to target and detect the tumor vasculature in the living mice as a theranostic agent.

4.6. Dendrimers

Dendrimers are three-dimensional spherical-shaped nanobiomaterials with repeated branches of dendron which contains a single chemical group, called a focal point [157, 158]. The structure of dendrimers consists of a core of initiator, repeated branching units, terminal functional groups, and void spaces, which are rooms for molecular cargo [159]. In the globular and nanosized structures of dendrimers, the terminal functional groups of the outer surface are essential in determining the properties of dendritic macromolecules, which can be interacted and conjugated with other molecules to target the cancer cells and tissues. The commonly used dendrimers in nanomedicines are polyamidoamines (PAMAM) [160], poly(L-lysine) scaffold dendrimers (PLL) [161], polyesters (PGLSA-OH) [162], polypropylimines (PPI) [163], and poly(2,2-bis(hydroxymethyl) propionic acid scaffold dendrimers (bis-MPA) [164]. Some of them are commercially available such as PAMAM dendrimers (Starburst) and PPI dendrimers (Astramol) [165, 166]. Dendrimers can be applied to cancer targeting conjugated with the targeting ligands such as folate, transferrin, antibodies, peptides, and aptamers [167]. In addition, multifunctionality of dendrimers can be a major advantage based on an incorporation of anticancer therapeutics as well as imaging agents [158, 165, 168].

4.7. Virus-Based Nanoplatforms (Phage System)

Virus-based nanomaterials have been dramatically investigated in recent years [169]. Viruses are biochemical complexes composed of genomic and proteomic materials. The desired functions of materials for bionanomedicine can be engineered by designing the shape and size of nanoparticles as well as the specific sequence of DNA and proteins. The self-assembled viral architecture can occur in a wide range of shapes and sizes [170] and can offer remarkable structural features of virus that make them excellent candidates for bionanomedicine [171, 172]. Advancements in nanoscale biological engineering of viral particles provide a development of novel pathways to develop nanomedicine for cancer therapeutics. Various types of viruses, such as adenovirus, adeno-associated virus, and bacteriophages, have been utilized for targeted cancer therapy and imaging through genetic and chemical modifications of the virus [173175].

A bacteriophage (phage) is a prokaryotic virus that can infect the bacterial host cells exploiting the host’s biosynthetic machinery to produce many identical copies of the phage itself [176]. There are many types of phages with different genomic materials, replication processes, and shapes such as linear (M13, Fd, and F1) [177] or spherical (MS2) [178]. Some shapes are quite sophisticated; for example, T4 and T7 phages possess an icosahedral head and a long tail connected through a cylindrical body [170]. Over the last two decades, the biochemical landscape of the phage structure has been greatly expanded through genetic engineering [179182] and site-specific organic synthesis approaches [183186]. Through genetic engineering, many foreign or synthetic DNAs have been integrated into the phage genome and expressed at various sites of the phage body [182, 187]. Several groups are investigating the engineered filamentous bacteriophage for in vivo screening via phage display within organs [188] or cancerous tissue [189, 190], for the purpose of targeted drug delivery [191, 192] or as an imaging agent [193]. For gene delivery applications, therapeutic genetic material can be incorporated into the phage DNA and carried into the cells following a receptor uptake [194]. The phage can be locally targeted to the cell receptors by incorporation of specific targeting and/or internalization peptides (i.e., via RGD or other ligands). To make the phage even more effective than the DNA delivery vehicles, phage can be further decorated with peptides that facilitate endosomal escape or nuclear localization motifs that target the nuclear envelope [195]. The most widely used bacteriophages for gene delivery are M13 filamentous phages [173, 196, 197] and lambda phages [198]. To enhance gene delivery efficiency, the phage with the multifunctional peptides can be produced using a phagemid system, which facilitates manipulation of expressed proteins on viral vectors [197]. Phage display technology has allowed for identification of novel homing peptides that target the unknown cell surface proteins. The targeting peptides can be incorporated into the phage coat proteins through genetic engineering techniques or chemical modifications to improve targeting efficiency [194]. These include peptides (RGD, glioma-binding peptide) [197, 199], HER2 receptor targeting antibody [173], growth factors (EGF and FGF2) [200, 201], and the penton base of adenovirus [198]. Hajitou et al. constructed a hybrid phage with two genes from the phage and nucleus integrating gene from an adeno-associated virus (AAV), called inverted terminal repeats [194]. Although eukaryotic viruses such as AAV have fantastic transgene delivery capabilities, they require an elimination of the native tropism for mammalian cells. In contrast, M13 phages have no tropism for mammalian cells; however, their gene delivery efficiency is poor. Thus, there has been an effort to combine the advantageous aspects of AAV and M13 phages into a single system [194]. This phage displayed integrin-binding peptides (cyclic RGD) on the minor coat proteins and carried the herpes simplex virus thymidine kinase gene (HSVtk). The resulting AAV/phage system provided a superior tumor transduction over the phage alone and was used as the PET imaging agent with [18F]FDG and [18F]FEAU as well as cancer therapeutics with ganciclovir treatment (Table 1). Ghosh et al. investigated the selective tumor targeting phage-based material for in vivo imaging for prostate cancer, acidic and rich in cysteine (SPARC), which is upregulated in various cancers and correlated with poor prognosis [202]. The capsid organization of M13 spatially separates the targeting and imaging moieties. Using p3 to display the targeting ligands (SPARC-binding peptide, SPPTGIN) while assembling multiple magnetic iron oxide nanoparticles (MNPs) along the p8 capsid achieves effective targeting and delivers a larger payload of MNPs per SPARC compared with directly functionalized nanoparticles (Table 1). Compared with nanoparticles that are directly functionalized with targeting peptides, this approach improves the contrast because each SPARC-targeting molecule delivers a larger number of nanoparticles into the cells. Moreover, the targeting ligand and nanoparticles could be easily exchanged for others, making this platform attractive for in vivo screening and molecular detection (Table 1).

5. Applications of Targeted Delivery Systems from Cells to Clinics

Nanoplatforms generally have the potential to be applied as cancer diagnosis, imaging, and treatment in vitro and in vivo. Targeted delivery strategies of nanoplatforms are special formulations and carriers with anticancer drugs such as pegylated liposomes, polymeric nanoparticles/micelles, and albumin-based drug carriers. These nanoplatforms that we mentioned above can be applicable to the biomedical approaches such as cancer diagnostics [145], anticancer therapy [203], nanoimaging [204], bimodal imaging [205, 206], and real-time intraoperative imaging [26]. The FDA has approved clinical use of a significant number of anticancer drug products in the nanometer size range including the applications in Table 3. In particular, nanoimaging has become based on the diagnostic potential of an earlier detection in the cancer and other human diseases [207]. In the case of bimodal contrast imaging, bimodal contrast agents allow the assessment of regions of interest using two independent imaging modalities such as MRI reagents and fluorescent agents. In the case of MRI and fluorescence imaging, MRI has an excellent spatial resolution, and fluorescence imaging compensates for the sensitivity of MRI overcoming the limitations of a single-modality imaging [208]. For intraoperative fluorescence imaging, the first human trial in advanced-stage ovarian cancer proceeded with tumor-specific folate receptor-α targeted fluorescent agent [26]. This study offers the potential application of intraoperative staging with tumor-specific fluorescence imaging in patients with ovarian cancer by folate receptor-α overexpression.

6. Conclusion

Human genomic map has accelerated the current biomedical application for the improvement of human healthcare and future therapies encompassing a full understanding of the gene function. Increasing information regarding the gene regulation process will provide the fundamental knowledge for the development of novel therapy in the disease state of cancer. For this streamline of biomedical research, nanoplatforms can take the center stage of participating in the development of targeted nanomedicine for anticancer therapy in the foreseeable future. Using these nanoplatform techniques, targeted anticancer therapy of nanomedicine without toxicity will be able to detect, confirm, and treat various types of cancers as a part of personalized medicine. This therapeutic potential will require more approaches to develop ideal targeted nanoplatforms overcoming toxicity and enhancing biocompatibility, as well as multifunctionality of nanoplatforms. We believe that these cancer targeting studies of nanoplatforms can contribute to the scientific achievement of nanotechnology and nanoplatforms for the development of targeted anticancer therapeutics.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


This work is supported by Korean Health Technology R&D Project (A120266), Ministry of Health and Welfare, the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2012-0002988, 2012R1A2A2A01045602), and Inha University grant.


  1. American Cancer Society, Cancer Facts and Figures 2013, American Cancer Society, Atlanta, Ga, USA, 2013.
  2. S. Svenson, “Clinical translation of nanomedicines,” Current Opinion in Solid State and Materials Science, vol. 16, no. 6, pp. 287–294, 2012. View at: Publisher Site | Google Scholar
  3. A. M. Mohs and J. M. Provenzale, “Applications of nanotechnology to imaging and therapy of brain tumors,” Neuroimaging Clinics of North America, vol. 20, no. 3, pp. 283–292, 2010. View at: Publisher Site | Google Scholar
  4. Y.-E. L. Koo, G. R. Reddy, M. Bhojani et al., “Brain cancer diagnosis and therapy with nanoplatforms,” Advanced Drug Delivery Reviews, vol. 58, no. 14, pp. 1556–1577, 2006. View at: Publisher Site | Google Scholar
  5. National Nanotechnology Initiative (NNI), “What is nanotechnology?” View at: Google Scholar
  6. H. S. Choi and J. V. Frangioni, “Nanoparticles for biomedical imaging: fundamentals of clinical translation,” Molecular Imaging, vol. 9, no. 6, pp. 291–310, 2010. View at: Publisher Site | Google Scholar
  7. J. Shi, A. R. Votruba, O. C. Farokhzad, and R. Langer, “Nanotechnology in drug delivery and tissue engineering: from discovery to applications,” Nano Letters, vol. 10, no. 9, pp. 3223–3230, 2010. View at: Publisher Site | Google Scholar
  8. L. Zhang, F. X. Gu, J. M. Chan, A. Z. Wang, R. S. Langer, and O. C. Farokhzad, “Nanoparticles in medicine: therapeutic applications and developments,” Clinical Pharmacology and Therapeutics, vol. 83, no. 5, pp. 761–769, 2007. View at: Google Scholar
  9. T. Lammers, W. E. Hennink, and G. Storm, “Tumour-targeted nanomedicines: principles and practice,” British Journal of Cancer, vol. 99, no. 3, pp. 392–397, 2008. View at: Publisher Site | Google Scholar
  10. T. Lammers, F. Kiessling, W. E. Hennink, and G. Storm, “Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress,” Journal of Controlled Release, vol. 161, no. 2, pp. 175–187, 2012. View at: Publisher Site | Google Scholar
  11. D. W. Northfelt, B. J. Dezube, J. A. Thommes et al., “Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial,” Journal of Clinical Oncology, vol. 16, no. 7, pp. 2445–2451, 1998. View at: Google Scholar
  12. R. Strother and D. Matei, “Pegylated liposomal doxorubicin in ovarian cancer,” Therapeutics and Clinical Risk Management, vol. 5, no. 3, pp. 639–650, 2009. View at: Google Scholar
  13. A. D. Bangham, M. M. Standish, and J. C. Watkins, “Diffusion of univalent ions across the lamellae of swollen phospholipids,” Journal of Molecular Biology, vol. 13, no. 1, pp. 238–252, 1965. View at: Google Scholar
  14. K. Sen and M. Mandal, “Second generation liposomal cancer therapeutics: transition from laboratory to clinic,” International Journal of Pharmaceutics, vol. 448, no. 1, pp. 28–43, 2013. View at: Publisher Site | Google Scholar
  15. H. Maeda, H. Nakamura, and J. Fang, “The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo,” Advanced Drug Delivery Reviews, vol. 65, no. 1, pp. 71–79, 2013. View at: Publisher Site | Google Scholar
  16. O. C. Farokhzad and R. Langer, “Impact of nanotechnology on drug delivery,” ACS Nano, vol. 3, no. 1, pp. 16–20, 2009. View at: Publisher Site | Google Scholar
  17. M. Zhao, M. Yang, X.-M. Li et al., “Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 3, pp. 755–760, 2005. View at: Publisher Site | Google Scholar
  18. N. T. Kimura, S. Taniguchi, K. Aoki, and T. Baba, “Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration,” Cancer Research, vol. 40, no. 6, pp. 2061–2068, 1980. View at: Google Scholar
  19. Y. Matsumura and H. Maeda, “A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs,” Cancer Research, vol. 46, no. 12, part 1, pp. 6387–6392, 1986. View at: Google Scholar
  20. J. Fang, H. Nakamura, and H. Maeda, “The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect,” Advanced Drug Delivery Reviews, vol. 63, no. 3, pp. 136–151, 2011. View at: Publisher Site | Google Scholar
  21. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom, “Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation,” European Journal of Cancer, vol. 37, no. 13, pp. 1590–1598, 2001. View at: Publisher Site | Google Scholar
  22. T. M. Allen and P. R. Cullis, “Drug delivery systems: entering the mainstream,” Science, vol. 303, no. 5665, pp. 1818–1822, 2004. View at: Publisher Site | Google Scholar
  23. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, “Nanocarriers as an emerging platform for cancer therapy,” Nature Nanotechnology, vol. 2, no. 12, pp. 751–760, 2007. View at: Publisher Site | Google Scholar
  24. M. E. Davis, Z. Chen, and D. M. Shin, “Nanoparticle therapeutics: an emerging treatment modality for cancer,” Nature Reviews Drug Discovery, vol. 7, no. 9, pp. 771–782, 2008. View at: Publisher Site | Google Scholar
  25. R. K. Jain and T. Stylianopoulos, “Delivering nanomedicine to solid tumors,” Nature Reviews Clinical Oncology, vol. 7, no. 11, pp. 653–664, 2010. View at: Publisher Site | Google Scholar
  26. G. M. Van Dam, G. Themelis, L. M. A. Crane et al., “Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results,” Nature Medicine, vol. 17, no. 10, pp. 1315–1319, 2011. View at: Publisher Site | Google Scholar
  27. L. W. Seymour, D. R. Ferry, D. Anderson et al., “Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin,” Journal of Clinical Oncology, vol. 20, no. 6, pp. 1668–1676, 2002. View at: Publisher Site | Google Scholar
  28. G. D. Lewis Phillips, G. Li, D. L. Dugger et al., “Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate,” Cancer Research, vol. 68, no. 22, pp. 9280–9290, 2008. View at: Publisher Site | Google Scholar
  29. Z. M. Qian, H. Li, H. Sun, and K. Ho, “Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway,” Pharmacological Reviews, vol. 54, no. 4, pp. 561–587, 2002. View at: Publisher Site | Google Scholar
  30. B. Gupta, T. S. Levchenko, and V. P. Torchilin, “Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides,” Advanced Drug Delivery Reviews, vol. 57, no. 4, pp. 637–651, 2005. View at: Publisher Site | Google Scholar
  31. D. Neri and R. Bicknell, “Tumour vascular targeting,” Nature Reviews Cancer, vol. 5, no. 6, pp. 436–446, 2005. View at: Publisher Site | Google Scholar
  32. K. Temming, R. M. Schiffelers, G. Molema, and R. J. Kok, “RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature,” Drug Resistance Updates, vol. 8, no. 6, pp. 381–402, 2005. View at: Publisher Site | Google Scholar
  33. R. Pasqualini, E. Koivunen, R. Kain et al., “Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis,” Cancer Research, vol. 60, no. 3, pp. 722–727, 2000. View at: Google Scholar
  34. Y. Matsumura and K. Kataoka, “Preclinical and clinical studies of anticancer agent-incorporating polymer micelles,” Cancer Science, vol. 100, no. 4, pp. 572–579, 2009. View at: Publisher Site | Google Scholar
  35. S. Nie, “Editorial: understanding and overcoming major barriers in cancer nanomedicine,” Nanomedicine, vol. 5, no. 4, pp. 523–528, 2010. View at: Publisher Site | Google Scholar
  36. F. Perche and V. P. Torchilin, “Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting,” Journal of Drug Delivery, vol. 2013, Article ID 705265, 32 pages, 2013. View at: Publisher Site | Google Scholar
  37. A. Srivastavaa, I. B. O. ’Connora, A. Panditb, and J. G. Wall, “Polymer-antibody fragment conjugates for biomedical applications,” Progress in Polymer Science, 2013. View at: Publisher Site | Google Scholar
  38. P. E. Kintzel and R. T. Dorr, “Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function,” Cancer Treatment Reviews, vol. 21, no. 1, pp. 33–64, 1995. View at: Publisher Site | Google Scholar
  39. A. Remesh, “Toxicities of anticancer drugs and its management,” International Journal of Basic & Clinical Pharmacology, vol. 1, no. 1, pp. 2–12, 2012. View at: Google Scholar
  40. R. K. Jain and T. Stylianopoulos, “Delivering nanomedicine to solid tumors,” Nature Reviews Clinical Oncology, vol. 7, no. 11, pp. 653–664, 2010. View at: Publisher Site | Google Scholar
  41. N. Kamaly, Z. Xiao, P. M. Valencia, A. F. Radovic-Moreno, and O. C. Farokhzad, “Targeted polymeric therapeutic nanoparticles: design, development and clinical translation,” Chemical Society Reviews, vol. 41, no. 7, pp. 2971–3010, 2012. View at: Publisher Site | Google Scholar
  42. D. C. Julien, S. Behnke, G. Wang, G. K. Murdoch, and R. A. Hill, “Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer,” mAbs, vol. 3, no. 5, pp. 467–478, 2011. View at: Publisher Site | Google Scholar
  43. J. Kopeček, “Polymer-drug conjugates: origins, progress to date and future directions,” Advanced Drug Delivery Reviews, vol. 65, no. 1, pp. 49–59, 2013. View at: Publisher Site | Google Scholar
  44. A. Accardo, D. Tesauro, and G. Morelli, “Peptide-based targeting strategies for simultaneous imaging and therapy with nanovectors,” Polymer Journal, vol. 45, no. 5, pp. 481–493, 2013. View at: Publisher Site | Google Scholar
  45. S. Sofou, “Surface-active liposomes for targeted cancer therapy,” Nanomedicine, vol. 2, no. 5, pp. 711–724, 2007. View at: Publisher Site | Google Scholar
  46. M. Wang and M. Thanou, “Targeting nanoparticles to cancer,” Pharmacological Research, vol. 62, no. 2, pp. 90–99, 2010. View at: Publisher Site | Google Scholar
  47. O. Tacar, P. Sriamornsak, and C. R. Dass, “Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems,” Journal of Pharmacy and Pharmacology, vol. 65, no. 2, pp. 157–170, 2013. View at: Publisher Site | Google Scholar
  48. M. Volkova and R. Russell III, “Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment,” Current Cardiology Reviews, vol. 7, no. 4, pp. 214–220, 2011. View at: Google Scholar
  49. V. Krishnan and A. K. Rajasekaran, “Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy,” Clinical Pharmacology and Therapeutics, 2013. View at: Publisher Site | Google Scholar
  50. R. van der Meela, L. J. C. Vehmeijera, R. J. Koka, G. Storma, and E. V. B. van Gaala, “Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status,” Advanced Drug Delivery Reviews, vol. 65, no. 10, pp. 1284–1298, 2013. View at: Publisher Site | Google Scholar
  51. D. Y. Alakhova, Y. Zhao, S. Li, and A. V. Kabanov, “Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia,” PloS ONE, vol. 8, no. 8, Article ID e72238, 2013. View at: Publisher Site | Google Scholar
  52. Y. Matsumura, T. Hamaguchi, T. Ura et al., “Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin,” British Journal of Cancer, vol. 91, no. 10, pp. 1775–1781, 2004. View at: Publisher Site | Google Scholar
  53. P. Cozzi, N. Mongelli, and A. Suarato, “Recent anticancer cytotoxic agents,” Current Medicinal Chemistry-Anti-Cancer Agents, vol. 4, no. 2, pp. 93–121, 2004. View at: Publisher Site | Google Scholar
  54. E. K. Rowinsky, M. Wright, B. Monsarrat, and R. C. Donehower, “Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993,” Annals of Oncology, vol. 5, supplement, pp. S7–S16, 1994. View at: Google Scholar
  55. E. K. Rowinsky and R. C. Donehower, “Drug therapy: paclitaxel (taxol),” The New England Journal of Medicine, vol. 332, no. 15, pp. 1004–1014, 1995. View at: Publisher Site | Google Scholar
  56. H. A. Azim Jr. and A. Awada, “Clinical development of new formulations of cytotoxics in solid tumors,” Current Opinion in Oncology, vol. 24, no. 3, pp. 325–331, 2012. View at: Publisher Site | Google Scholar
  57. U. Fasol, A. Frost, M. Büchert et al., “Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis,” Annals of Oncology, vol. 23, no. 4, pp. 1030–1036, 2012. View at: Publisher Site | Google Scholar
  58. S. Koudelka and J. Turanek, “Liposomal paclitaxel formulations,” Journal of Controlled Release, vol. 163, no. 3, pp. 322–334, 2012. View at: Google Scholar
  59. T.-Y. Kim, D.-W. Kim, J.-Y. Chung et al., “Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies,” Clinical Cancer Research, vol. 10, no. 11, pp. 3708–3716, 2004. View at: Publisher Site | Google Scholar
  60. T. Negishi, F. Koizumi, H. Uchino et al., “NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel,” British Journal of Cancer, vol. 95, no. 5, pp. 601–606, 2006. View at: Publisher Site | Google Scholar
  61. V. L. Galic, T. J. Herzog, J. D. Wright, and S. N. Lewin, “Paclitaxel poliglumex for ovarian cancer,” Expert Opinion on Investigational Drugs, vol. 20, no. 6, pp. 813–821, 2011. View at: Publisher Site | Google Scholar
  62. T. Hamaguchi, Y. Matsumura, M. Suzuki et al., “NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel,” British Journal of Cancer, vol. 92, no. 7, pp. 1240–1246, 2005. View at: Publisher Site | Google Scholar
  63. X. Wang and Z. Guo, “Targeting and delivery of platinum-based anticancer drugs,” Chemical Society Reviews, vol. 42, no. 1, pp. 202–2224, 2013. View at: Publisher Site | Google Scholar
  64. J. S. Butler and P. J. Sadler, “Targeted delivery of platinum-based anticancer complexes,” Current Opinion in Chemical Biology, vol. 17, no. 2, pp. 175–188, 2013. View at: Publisher Site | Google Scholar
  65. W. C. Zamboni, “Concept and clinical evaluation of carrier-mediated anticancer agents,” Oncologist, vol. 13, no. 3, pp. 248–260, 2008. View at: Publisher Site | Google Scholar
  66. R. Plummer, R. H. Wilson, H. Calvert et al., “A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours,” British Journal of Cancer, vol. 104, no. 4, pp. 593–598, 2011. View at: Publisher Site | Google Scholar
  67. I. Kümler, N. Brünner, J. Stenvang, E. Balslev, and D. L. Nielsen, “A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer,” Breast Cancer Research and Treatment, vol. 138, no. 2, pp. 347–358, 2013. View at: Publisher Site | Google Scholar
  68. L. Zhang, Y. Hu, X. Jiang, C. Yang, W. Lu, and Y. H. Yang, “Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b- poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice,” Journal of Controlled Release, vol. 96, no. 1, pp. 135–148, 2004. View at: Publisher Site | Google Scholar
  69. W. C. Zamboni, S. Ramalingam, D. M. Friedland et al., “Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies,” Clinical Cancer Research, vol. 15, no. 4, pp. 1466–1472, 2009. View at: Publisher Site | Google Scholar
  70. C. Young, T. Schluep, J. Hwang, and S. Eliasof, “CRLX101 (formerly IT-101)-A novel nanopharmaceutical of camptothecin in clinical development,” Current Bioactive Compounds, vol. 7, no. 1, pp. 8–14, 2011. View at: Publisher Site | Google Scholar
  71. T. Hamaguchi, T. Doi, T. Eguchi-Nakajima et al., “Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors,” Clinical Cancer Research, vol. 16, no. 20, pp. 5058–5066, 2010. View at: Publisher Site | Google Scholar
  72. D. H. Palmer, L. S. Young, and V. Mautner, “Cancer gene-therapy: clinical trials,” Trends in Biotechnology, vol. 24, no. 2, pp. 76–82, 2006. View at: Publisher Site | Google Scholar
  73. L. Xu, W.-H. Tang, C.-C. Huang et al., “Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv,” Molecular Medicine, vol. 7, no. 10, pp. 723–734, 2001. View at: Google Scholar
  74. K. F. Pirollo, A. Rait, Q. Zhou et al., “Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo,” Clinical Cancer Research, vol. 14, no. 7, pp. 2190–2198, 2008. View at: Publisher Site | Google Scholar
  75. D. W. Bartlett, H. Su, I. J. Hildebrandt, W. A. Weber, and M. E. Davis, “Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 39, pp. 15549–15554, 2007. View at: Publisher Site | Google Scholar
  76. P. P. Deshpande, S. Biswas, and V. P. Torchilin, “Current trends in the use of liposomes for tumor targeting,” Nanomedicine, vol. 8, no. 9, pp. 1509–1528, 2013. View at: Google Scholar
  77. W. T. Al-Jamal and K. Kostarelos, “Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine,” Accounts of Chemical Research, vol. 44, no. 10, pp. 1094–1104, 2011. View at: Publisher Site | Google Scholar
  78. G. Gregoriadis, “The carrier potential of liposomes in biology and medicine. II,” The New England Journal of Medicine, vol. 295, no. 14, pp. 765–770, 1976. View at: Google Scholar
  79. J. L. Arias, “Liposomes in drug delivery: a patent review (2007-present),” Expert Opinion on Therapeutic Patents, vol. 23, no. 11, pp. 1399–1414, 2013. View at: Publisher Site | Google Scholar
  80. M. R. Preiss and G. D. Bothun, “Stimuli-responsive liposome-nanoparticle assemblies,” Expert Opinion on Drug Delivery, vol. 8, no. 8, pp. 1025–1040, 2011. View at: Publisher Site | Google Scholar
  81. A. S. Manjappa, K. R. Chaudhari, M. P. Venkataraju et al., “Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor,” Journal of Controlled Release, vol. 150, no. 1, pp. 2–22, 2011. View at: Publisher Site | Google Scholar
  82. Y. Zhao, S. Zhang, S. Cui, B. Wang, and S. Zhang, “Peptide-based cationic liposome-mediated gene delivery,” Expert Opinion on Drug Delivery, vol. 9, no. 1, pp. 127–139, 2012. View at: Publisher Site | Google Scholar
  83. M. L. Immordino, F. Dosio, and L. Cattel, “Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential,” International Journal of Nanomedicine, vol. 1, no. 3, pp. 297–315, 2006. View at: Google Scholar
  84. N. K. Mehra, V. Mishra, and N. K. Jain, “Receptor-based targeting of therapeutics,” Therapeutic Delivery, vol. 4, no. 3, pp. 369–394, 2013. View at: Google Scholar
  85. M. Amin, A. Badiee, and M. R. Jaafari, “Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas,” International Journal of Pharmaceutics, vol. 458, no. 2, pp. 324–333. View at: Publisher Site | Google Scholar
  86. X. Liu, S. Ma, C. Dai et al., “Antiproliferative, antiinvasive, and proapoptotic activity of folate receptor alpha-targeted liposomal doxorubicin in nonfunctional pituitary adenoma cells,” Endocrinology, vol. 154, no. 4, pp. 1414–1423, 2013. View at: Publisher Site | Google Scholar
  87. B. Xiang, D.-W. Dong, N.-Q. Shi et al., “PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer,” Biomaterials, vol. 34, no. 28, pp. 6976–6991, 2013. View at: Publisher Site | Google Scholar
  89. C. Brignole, D. Marimpietri, G. Pagnan et al., “Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities,” Cancer Letters, vol. 228, no. 1-2, pp. 181–186, 2005. View at: Publisher Site | Google Scholar
  90. F. Moret, D. Scheglmann, and E. Reddi, “Folate-targeted PEGylated liposomes improve the selectivity of PDT with meta-tetra(hydroxyphenyl)chlorin (m-THPC),” Photochemical & Photobiological Sciences, vol. 12, no. 5, pp. 823–834, 2013. View at: Google Scholar
  91. Z. Zhang and J. Yao, “Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity,” AAPS PharmSciTech, vol. 13, no. 3, pp. 802–810, 2012. View at: Publisher Site | Google Scholar
  92. K. F. Yu, W. Q. Zhang, L. M. Luo et al., “The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation,” International Journal of Nanomedicine, vol. 8, pp. 2473–2485, 2013. View at: Publisher Site | Google Scholar
  93. A. Wicki, C. Rochlitz, A. Orleth et al., “Targeting tumor-associated endothelial cells: Anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth,” Clinical Cancer Research, vol. 18, no. 2, pp. 454–464, 2012. View at: Publisher Site | Google Scholar
  94. C. Ma, X. Li, X. liang, K. Jin, J. Cao, and W. Xu, “Novel beta-dicarbonyl derivatives as inhibitors of aminopeptidase N (APN),” Bioorganic & Medicinal Chemistry Letters, vol. 23, no. 17, pp. 4948–4952, 2013. View at: Publisher Site | Google Scholar
  95. A. H. Negussie, J. L. Miller, G. Reddy, S. K. Drake, B. J. Wood, and M. R. Dreher, “Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome,” Journal of Controlled Release, vol. 143, no. 2, pp. 265–273, 2010. View at: Publisher Site | Google Scholar
  96. S. Tan, X. Li, Y. Guo, and Z. Zhang, “Lipid-enveloped hybrid nanoparticles for drug delivery,” Nanoscale, vol. 5, no. 3, pp. 860–872, 2013. View at: Publisher Site | Google Scholar
  97. G. Von Maltzahn, J.-H. Park, K. Y. Lin et al., “Nanoparticles that communicate in vivo to amplify tumour targeting,” Nature Materials, vol. 10, no. 7, pp. 545–552, 2011. View at: Publisher Site | Google Scholar
  98. W. Huang, J. Zhang, H. C. Dorn, and C. Zhang, “Assembly of bio-nanoparticles for double controlled drug release,” PLoS ONE, vol. 8, no. 9, Article ID e74679, 2013. View at: Publisher Site | Google Scholar
  99. F. Karchemski, D. Zucker, Y. Barenholz, and O. Regev, “Carbon nanotubes-liposomes conjugate as a platform for drug delivery into cells,” Journal of Controlled Release, vol. 160, no. 2, pp. 339–345, 2012. View at: Publisher Site | Google Scholar
  100. A. S. Narang, R. K. Chang, and M. A. Hussain, “Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems,” Journal of Pharmaceutical Sciences, vol. 102, no. 11, pp. 3867–3882, 2013. View at: Google Scholar
  101. R. Duncan, “Polymer conjugates as anticancer nanomedicines,” Nature Reviews Cancer, vol. 6, no. 9, pp. 688–701, 2006. View at: Publisher Site | Google Scholar
  102. S. S. Banerjee, N. Aher, R. Patil, and J. Khandare, “Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications,” Journal of Drug Delivery, vol. 2012, Article ID 103973, 17 pages, 2012. View at: Publisher Site | Google Scholar
  103. H. Sah, L. A. Thoma, H. R. Desu, E. Sah, and G. C. Wood, “Concepts and practices used to develop functional PLGA-based nanoparticulate systems,” International Journal of Nanomedicine, vol. 8, pp. 747–765, 2013. View at: Publisher Site | Google Scholar
  104. F. Danhier, E. Ansorena, J. M. Silva, R. Coco, A. Le Breton, and V. Préat, “PLGA-based nanoparticles: an overview of biomedical applications,” Journal of Controlled Release, vol. 161, no. 2, pp. 505–522, 2012. View at: Publisher Site | Google Scholar
  105. S. Acharya and S. K. Sahoo, “PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect,” Advanced Drug Delivery Reviews, vol. 63, no. 3, pp. 170–183, 2011. View at: Publisher Site | Google Scholar
  106. F. Danhier, N. Lecouturier, B. Vroman et al., “Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation,” Journal of Controlled Release, vol. 133, no. 1, pp. 11–17, 2009. View at: Publisher Site | Google Scholar
  107. J. Liang, Y. Luo, and H. Zhao, “Synthetic biology: putting synthesis into biology,” Wiley Interdisciplinary Reviews, vol. 3, no. 1, pp. 7–20, 2011. View at: Publisher Site | Google Scholar
  108. W. Hasan, K. Chu, A. Gullapalli et al., “Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer,” Nano Letters, vol. 12, no. 1, pp. 287–292, 2012. View at: Publisher Site | Google Scholar
  109. C. Chittasupho, S.-X. Xie, A. Baoum, T. Yakovleva, T. J. Siahaan, and C. J. Berkland, “ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells,” European Journal of Pharmaceutical Sciences, vol. 37, no. 2, pp. 141–150, 2009. View at: Publisher Site | Google Scholar
  110. C. Liang, Y. Yang, Y. Ling, Y. Huang, T. Li, and X. Li, “Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma,” Bioorganic and Medicinal Chemistry, vol. 19, no. 13, pp. 4057–4066, 2011. View at: Publisher Site | Google Scholar
  111. H. Zhao and L. Y. L. Yung, “Addition of TPGS to folate-conjugated polymer micelles for selective tumor targeting,” Journal of Biomedical Materials Research - Part A, vol. 91, no. 2, pp. 505–518, 2009. View at: Publisher Site | Google Scholar
  112. R. M. Taylor, V. Severns, D. C. Brown, M. Bisoffi, and L. O. Sillerud, “Prostate cancer targeting motifs: Expression of αvβ3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts,” Prostate, vol. 72, no. 5, pp. 523–532, 2012. View at: Publisher Site | Google Scholar
  113. S. Dhar, F. X. Gu, R. Langer, O. C. Farokhza, and S. J. Lippard, “Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA - PEG nanoparticles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 45, pp. 17356–17361, 2008. View at: Publisher Site | Google Scholar
  114. F. Danhier, V. Pourcelle, J. Marchand-Brynaert, C. Jérôme, O. Feron, and V. Préat, “Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles,” Methods in Enzymology, vol. 508, pp. 157–175, 2012. View at: Publisher Site | Google Scholar
  115. R. Hassert, P. G. Hoffmeister, M. Pagel, M. Hacker, M. Schulz-Siegmund, and A. G. Beck-Sickinger, “On-resin synthesis of an acylated and fluorescence-labeled cyclic integrin ligand for modification of poly(lactic-co-glycolic acid),” Chemistry & Biodiversity, vol. 9, no. 11, pp. 2648–2658, 2012. View at: Publisher Site | Google Scholar
  116. A. Aravind, P. Jeyamohan, R. Nair et al., “AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery,” Biotechnology and Bioengineering, vol. 109, no. 11, pp. 2920–2931, 2012. View at: Publisher Site | Google Scholar
  117. J. Guo, X. Gao, L. Su et al., “Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery,” Biomaterials, vol. 32, no. 31, pp. 8010–8020, 2011. View at: Publisher Site | Google Scholar
  118. B. Fadeel, “Clear and present danger? Engineered nanoparticles and the immune system,” Swiss Medical Weekly, vol. 142, Article ID w13609, 2012. View at: Publisher Site | Google Scholar
  119. R. Becker, C. Dembek, L. A. White, and L. P. Garrison, “The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature,” Expert Review of Pharmacoeconomics & Outcomes Research, vol. 12, no. 6, pp. 775–793, 2012. View at: Publisher Site | Google Scholar
  120. S. Kommareddy, S. B. Tiwari, and M. M. Amiji, “Long-circulating polymeric nanovectors for tumor-selective gene delivery,” Technology in Cancer Research and Treatment, vol. 4, no. 6, pp. 615–625, 2005. View at: Google Scholar
  121. S. Raha, T. Paunesku, and G. Woloschak, “Peptide-mediated cancer targeting of nanoconjugates,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, vol. 3, no. 3, pp. 269–281, 2011. View at: Publisher Site | Google Scholar
  122. E. Segal and R. Satchi-Fainaro, “Design and development of polymer conjugates as anti-angiogenic agents,” Advanced Drug Delivery Reviews, vol. 61, no. 13, pp. 1159–1176, 2009. View at: Publisher Site | Google Scholar
  123. Y. Xiong, W. Jiang, Y. Shen et al., “A Poly(γ, l-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery,” Biomaterials, vol. 33, no. 29, pp. 7182–7193, 2012. View at: Publisher Site | Google Scholar
  124. X. Zhao, H. Li, and R. J. Lee, “Targeted drug delivery via folate receptors,” Expert Opinion on Drug Delivery, vol. 5, no. 3, pp. 309–319, 2008. View at: Publisher Site | Google Scholar
  125. X. B. Zhao and R. J. Lee, “Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor,” Advanced Drug Delivery Reviews, vol. 56, no. 8, pp. 1193–1204, 2004. View at: Publisher Site | Google Scholar
  126. L. Teng, J. Xie, and R. J. Lee, “Clinical translation of folate receptor-targeted therapeutics,” Expert Opinion on Drug Delivery, vol. 9, no. 8, pp. 901–908, 2012. View at: Publisher Site | Google Scholar
  127. G. L. Zwicke, G. A. Mansoori, and C. J. Jeffery, “Utilizing the folate receptor for active targeting of cancer nanotherapeutics,” Nano Reviews, vol. 3, pp. 18496–18506, 2012. View at: Google Scholar
  128. X. Ming, K. Carver, and L. Wu, “Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides,” Biomaterials, vol. 34, no. 32, pp. 7939–7949, 2013. View at: Google Scholar
  129. R. K. Mittapalli, X. Liu, C. E. Adkins et al., “Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model,” Molecular Cancer Therapeutics, vol. 12, no. 11, pp. 2389–2399, 2013. View at: Publisher Site | Google Scholar
  130. C. Boyer, M. R. Whittaker, V. Bulmus, J. Liu, and T. P. Davis, “The design and utility of polymer-stabilized iron-oxide nanoparticles for nanomedicine applications,” NPG Asia Materials, vol. 2, no. 1, pp. 23–30, 2010. View at: Publisher Site | Google Scholar
  131. B. Polyak and G. Friedman, “Magnetic targeting for site-specific drug delivery: Applications and clinical potential,” Expert Opinion on Drug Delivery, vol. 6, no. 1, pp. 53–70, 2009. View at: Publisher Site | Google Scholar
  132. J. Meng, J. Fan, G. Galiana et al., “LHRH-functionalized superparamagnetic iron oxide nanoparticles for breast cancer targeting and contrast enhancement in MRI,” Materials Science and Engineering C, vol. 29, no. 4, pp. 1467–1479, 2009. View at: Publisher Site | Google Scholar
  133. M. K. Yu, Y. Y. Jeong, J. Park et al., “Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo,” Angewandte Chemie - International Edition, vol. 47, no. 29, pp. 5362–5365, 2008. View at: Publisher Site | Google Scholar
  134. N. Kohler, C. Sun, J. Wang, and M. Zhang, “Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells,” Langmuir, vol. 21, no. 19, pp. 8858–8864, 2005. View at: Publisher Site | Google Scholar
  135. A. Figuerola, R. Di Corato, L. Manna, and T. Pellegrino, “From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications,” Pharmacological Research, vol. 62, no. 2, pp. 126–143, 2010. View at: Publisher Site | Google Scholar
  136. G. Shipp, “Ultrasensitive measurement of protein and nucleic acid biomarkers for earlier disease detection and more effective therapies,” Biotechnology Healthcare Journal, vol. 3, no. 2, pp. 35–40, 2006. View at: Google Scholar
  137. G. Peng, U. Tisch, O. Adams et al., “Diagnosing lung cancer in exhaled breath using gold nanoparticles,” Nature Nanotechnology, vol. 4, no. 10, pp. 669–673, 2009. View at: Publisher Site | Google Scholar
  138. C. S. Thaxton, R. Elghanian, A. D. Thomas et al., “Nanoparticle-based bio-barcode assay redefines “undetectable” PSA and biochemical recurrence after radical prostatectomy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 44, pp. 18437–18442, 2009. View at: Publisher Site | Google Scholar
  139. V. Singh, D. Joung, L. Zhai, S. Das, S. I. Khondaker, and S. Seal, “Graphene based materials: past, present and future,” Progress in Materials Science, vol. 56, no. 8, pp. 1178–1271, 2011. View at: Publisher Site | Google Scholar
  140. C. Cha, S. R. Shin, N. Annabi, M. R. Dokmeci, and A. Khademhosseini, “Carbon-based nanomaterials: multifunctional materials for biomedical engineering,” ACS Nano, vol. 7, no. 4, pp. 2891–2897, 2013. View at: Publisher Site | Google Scholar
  141. A. Biswas, I. S. Bayer, A. S. Biris, T. Wang, E. Dervishi, and F. Faupel, “Advances in top-down and bottom-up surface nanofabrication: techniques, applications & future prospects,” Advances in Colloid and Interface Science, vol. 170, no. 1-2, pp. 2–27, 2012. View at: Publisher Site | Google Scholar
  142. P. Sharma, V. Bhalla, E. S. Prasad, V. Dravid, G. Shekhawat, and C. R. Suri, “Enhancing graphene/CNT based electrochemical detection using magneto-nanobioprobes,” Scientific Reports, vol. 2, pp. 877–883, 2012. View at: Google Scholar
  143. K. Mallick and A. M. Strydom, “Biophilic carbon nanotubes,” Colloids and Surfaces B, vol. 105, pp. 310–318, 2013. View at: Publisher Site | Google Scholar
  144. B. Kateb, M. Van Handel, L. Zhang, M. J. Bronikowski, H. Manohara, and B. Badie, “Internalization of MWCNTs by microglia: possible application in immunotherapy of brain tumors,” NeuroImage, vol. 37, no. 1, pp. S9–S17, 2007. View at: Publisher Site | Google Scholar
  145. B. Kateb, K. Chiu, K. L. Black et al., “Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: What should be the policy?” NeuroImage, vol. 54, supplement 1, pp. S106–S124, 2011. View at: Publisher Site | Google Scholar
  146. A. Bianco, K. Kostarelos, C. D. Partidos, and M. Prato, “Biomedical applications of functionalised carbon nanotubes,” Chemical Communications, no. 5, pp. 571–577, 2005. View at: Publisher Site | Google Scholar
  147. A. Ruggiero, C. H. Villa, E. Bander et al., “Paradoxical glomerular filtration of carbon nanotubes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 27, pp. 12369–12374, 2010. View at: Publisher Site | Google Scholar
  148. Z. Liu, W. Cai, L. He et al., “in vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice,” Nature Nanotechnology, vol. 2, no. 1, pp. 47–52, 2007. View at: Publisher Site | Google Scholar
  149. C. Chung, Y.-K. Kim, D. Shin, S.-R. Ryoo, B. H. Hong, and D.-H. Min, “Biomedical applications of graphene and graphene oxide,” Accounts of Chemical Research, vol. 46, no. 10, pp. 2211–2224, 2013. View at: Publisher Site | Google Scholar
  150. M. Cai, D. Thorpe, D. H. Adamsonb, and H. C. Schniepp, “Methods of graphite exfoliation,” Journal of Materials Chemistry, vol. 22, no. 48, pp. 24992–25002, 2012. View at: Publisher Site | Google Scholar
  151. S. Z. Butler, S. M. Hollen, L. Cao et al., “Progress, challenges, and opportunities in two-dimensional materials beyond graphene,” ACS Nano, vol. 7, no. 4, pp. 2898–2926, 2013. View at: Publisher Site | Google Scholar
  152. H. Shen, L. Zhang, M. Liu, and Z. Zhang, “Biomedical applications of graphene,” Theranostics, vol. 2, no. 3, pp. 283–294, 2012. View at: Google Scholar
  153. D. R. Dreyer, S. Park, C. W. Bielawski, and R. S. Ruoff, “The chemistry of graphene oxide,” Chemical Society Reviews, vol. 39, no. 1, pp. 228–240, 2010. View at: Publisher Site | Google Scholar
  154. K. Yang, L. Feng, X. Shi, and Z. Liu, “Nano-graphene in biomedicine: theranostic applications,” Chemical Society Reviews, vol. 42, no. 2, pp. 530–547, 2013. View at: Publisher Site | Google Scholar
  155. S. Shi, K. Yang, H. Hong et al., “Tumor vasculature targeting and imaging in living mice with reduced graphene oxide,” Biomaterials, vol. 34, no. 12, pp. 3002–3009, 2013. View at: Publisher Site | Google Scholar
  156. K. Yang, S. Zhang, G. Zhang, X. Sun, S.-T. Lee, and Z. Liu, “Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy,” Nano Letters, vol. 10, no. 9, pp. 3318–3323, 2010. View at: Publisher Site | Google Scholar
  157. S. Svenson and D. A. Tomalia, “Dendrimers in biomedical applications: reflections on the field,” Advanced Drug Delivery Reviews, vol. 57, no. 15, pp. 2106–2129, 2005. View at: Publisher Site | Google Scholar
  158. A. R. Menjoge, R. M. Kannan, and D. A. Tomalia, “Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications,” Drug Discovery Today, vol. 15, no. 5-6, pp. 171–185, 2010. View at: Publisher Site | Google Scholar
  159. S. H. Medina and M. E. H. El-Sayed, “Dendrimers as carriers for delivery of chemotherapeutic agents,” Chemical Reviews, vol. 109, no. 7, pp. 3141–3157, 2009. View at: Publisher Site | Google Scholar
  160. Q. Xu, C.-H. Wang, and D. W. Pack, “Polymeric carriers for gene delivery: chitosan and poly(amidoamine) dendrimers,” Current Pharmaceutical Design, vol. 16, no. 21, pp. 2350–2368, 2010. View at: Publisher Site | Google Scholar
  161. R. Huang, L. Han, J. Li et al., “Chlorotoxin-modified macromolecular contrast agent for MRI tumor diagnosis,” Biomaterials, vol. 32, no. 22, pp. 5177–5186, 2011. View at: Publisher Site | Google Scholar
  162. M. T. Morgan, Y. Nakanishi, D. J. Kroll et al., “Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro,” Cancer Research, vol. 66, no. 24, pp. 11913–11921, 2006. View at: Publisher Site | Google Scholar
  163. F. Wang, X. Cai, Y. Su et al., “Reducing cytotoxicity while improving anti-cancer drug loading capacity of polypropylenimine dendrimers by surface acetylation,” Acta Biomaterialia, vol. 8, no. 12, pp. 4304–4313. View at: Publisher Site | Google Scholar
  164. A. Carlmark, E. Malmstrom, and M. Malkoch, “Dendritic architectures based on bis-MPA: functional polymeric scaffolds for application-driven research,” Chemical Society Reviews, vol. 42, no. 13, pp. 5858–5879, 2013. View at: Publisher Site | Google Scholar
  165. S. Svenson and A. S. Chauhan, “Dendrimers for enhanced drug solubilization,” Nanomedicine, vol. 3, no. 5, pp. 679–702, 2008. View at: Publisher Site | Google Scholar
  166. S. Svenson, “Dendrimers as versatile platform in drug delivery applications,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 71, no. 3, pp. 445–462, 2009. View at: Publisher Site | Google Scholar
  167. B. Yu, H. C. Tai, W. Xue, L. J. Lee, and R. J. Lee, “Receptor-targeted nanocarriers for therapeutic delivery to cancer,” Molecular Membrane Biology, vol. 27, no. 7, pp. 286–298, 2010. View at: Publisher Site | Google Scholar
  168. P. Kesharwani, V. Gajbhiye, and N. K. Jain, “A review of nanocarriers for the delivery of small interfering RNA,” Biomaterials, vol. 33, no. 29, pp. 7138–7150, 2012. View at: Google Scholar
  169. M. Sarikaya, C. Tamerler, A. K.-Y. Jen, K. Schulten, and F. Baneyx, “Molecular biomimetics: nanotechnology through biology,” Nature Materials, vol. 2, no. 9, pp. 577–585, 2003. View at: Publisher Site | Google Scholar
  170. R. Farr, D. S. Choi, and S. W. Lee, “Phage-based nanomaterials for biomedical applications,” Acta Biomaterialia, 2013. View at: Publisher Site | Google Scholar
  171. N. F. Steinmetz, “Viral nanoparticles as platforms for next-generation therapeutics and imaging devices,” Nanomedicine, vol. 6, no. 5, pp. 634–641, 2010. View at: Publisher Site | Google Scholar
  172. E. M. Plummer and M. Manchester, “Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design,” Wiley Interdisciplinary Reviews, vol. 3, no. 2, pp. 174–196, 2011. View at: Publisher Site | Google Scholar
  173. M.-A. Poul and J. D. Marks, “Targeted gene delivery to mammalian cells by filamentous bacteriophage,” Journal of Molecular Biology, vol. 288, no. 2, pp. 203–211, 1999. View at: Publisher Site | Google Scholar
  174. D. Frenkel and B. Solomon, “Filamentous phage as vector-mediated antibody delivery to the brain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 8, pp. 5675–5679, 2002. View at: Publisher Site | Google Scholar
  175. T. Nishimoto, K. Yoshida, Y. Miura et al., “Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob,” Gene Therapy, vol. 16, no. 5, pp. 669–680, 2009. View at: Publisher Site | Google Scholar
  176. S. E. Luria, “Bacteriophage: an essay on virus reproduction,” Science, vol. 111, no. 2889, pp. 507–511, 1950. View at: Google Scholar
  177. S. K. Straus, W. R. P. Scott, M. F. Symmons, and D. A. Marvin, “On the structures of filamentous bacteriophage Ff (fd, f1, M13),” European Biophysics Journal, vol. 37, no. 4, pp. 521–527, 2008. View at: Publisher Site | Google Scholar
  178. K. Valegard, L. Liljas, K. Fridborg, and T. Unge, “The three-dimensional structure of the bacterial virus MS2,” Nature, vol. 345, no. 6270, pp. 36–41, 1990. View at: Publisher Site | Google Scholar
  179. A. Merzlyak, S. Indrakanti, and S.-W. Lee, “Genetically engineered nanofiber-like viruses for tissue regenerating materials,” Nano Letters, vol. 9, no. 2, pp. 846–852, 2009. View at: Publisher Site | Google Scholar
  180. S. F. Parmley and G. P. Smith, “Antibody-selectable filamentous fd phage vectors: affinity purification of target genes,” Gene, vol. 73, no. 2, pp. 305–318, 1988. View at: Google Scholar
  181. J. K. Scott and G. P. Smith, “Searching for peptide ligands with an epitope library,” Science, vol. 249, no. 4967, pp. 386–390, 1990. View at: Google Scholar
  182. G. P. Smith and V. A. Petrenko, “Phage display,” Chemical Reviews, vol. 97, no. 2, pp. 391–410, 1997. View at: Google Scholar
  183. Z. M. Carrico, D. W. Romanini, R. A. Mehl, and M. B. Francis, “Oxidative coupling of peptides to a virus capsid containing unnatural amino acids,” Chemical Communications, no. 10, pp. 1205–1207, 2008. View at: Publisher Site | Google Scholar
  184. R. A. Miller, A. D. Presley, and M. B. Francis, “Self-assembling light-harvesting systems from synthetically modified tobacco mosaic virus coat proteins,” Journal of the American Chemical Society, vol. 129, no. 11, pp. 3104–3109, 2007. View at: Publisher Site | Google Scholar
  185. N. Stephanopoulos, Z. M. Carrico, and M. B. Francis, “Nanoscale integration of sensitizing chromophores and porphyrins with bacteriophage MS2,” Angewandte Chemie, vol. 48, no. 50, pp. 9498–9502, 2009. View at: Publisher Site | Google Scholar
  186. T. L. Schlick, Z. Ding, E. W. Kovacs, and M. B. Francis, “Dual-surface modification of the tobacco mosaic virus,” Journal of the American Chemical Society, vol. 127, no. 11, pp. 3718–3723, 2005. View at: Publisher Site | Google Scholar
  187. G. P. Smith, “Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface,” Science, vol. 228, no. 4705, pp. 1315–1317, 1985. View at: Google Scholar
  188. R. Pasqualini and E. Ruoslahti, “Organ targeting in vivo using phage display peptide libraries,” Nature, vol. 380, no. 6572, pp. 364–366, 1996. View at: Publisher Site | Google Scholar
  189. W. Arap, R. Pasqualini, and E. Ruoslahti, “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model,” Science, vol. 279, no. 5349, pp. 377–380, 1998. View at: Publisher Site | Google Scholar
  190. D. N. Krag, G. S. Shukla, G.-P. Shen et al., “Selection of tumor-binding ligands in cancer patients with phage display libraries,” Cancer Research, vol. 66, no. 15, pp. 7724–7733, 2006. View at: Publisher Site | Google Scholar
  191. T. J. Dickerson and K. D. Janda, “Recent advances for the treatment of cocaine abuse: central nervous system immunopharmacotherapy,” AAPS Journal, vol. 7, no. 3, pp. E579–E586, 2005. View at: Publisher Site | Google Scholar
  192. I. Yacoby, H. Bar, and I. Benhar, “Targeted drug-carrying bacteriophages as antibacterial nanomedicines,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 6, pp. 2156–2163, 2007. View at: Publisher Site | Google Scholar
  193. D. Frenkel and B. Solomon, “Filamentous phage as vector-mediated antibody delivery to the brain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 8, pp. 5675–5679, 2002. View at: Publisher Site | Google Scholar
  194. A. Hajitou, M. Trepel, C. E. Lilley et al., “A hybrid vector for ligand-directed tumor targeting and molecular imaging,” Cell, vol. 125, no. 2, pp. 385–398, 2006. View at: Publisher Site | Google Scholar
  195. M. E. Martin and K. G. Rice, “Peptide-guided gene delivery,” AAPS Journal, vol. 9, no. 1, pp. E18–E29, 2007. View at: Publisher Site | Google Scholar
  196. D. Larocca, A. Witte, W. Johnson, G. F. Pierce, and A. Baird, “Targeting bacteriophage to mammalian cell surface receptors for gene delivery,” Human Gene Therapy, vol. 9, no. 16, pp. 2393–2399, 1998. View at: Google Scholar
  197. J. D. Mount, T. I. Samoylova, N. E. Morrison, N. R. Cox, H. J. Baker, and V. A. Petrenko, “Cell targeted phagemid rescued by preselected landscape phage,” Gene, vol. 341, no. 1-2, pp. 59–65, 2004. View at: Publisher Site | Google Scholar
  198. S. Piersanti, G. Cherubini, Y. Martina et al., “Mammalian cell transduction and internalization properties of λ phages displaying the full-length adenoviral penton base or its central domain,” Journal of Molecular Medicine, vol. 82, no. 7, pp. 467–476, 2004. View at: Google Scholar
  199. S. L. Hart, A. M. Knight, R. P. Harbottle et al., “Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide,” Journal of Biological Chemistry, vol. 269, no. 17, pp. 12468–12474, 1994. View at: Google Scholar
  200. M. A. Burg, K. Jensen-Pergakes, A. M. Gonzalez, P. Ravey, A. Baird, and D. Larocca, “Enhanced phagemid particle gene transfer in camptothecin-treated carcinoma cells,” Cancer Research, vol. 62, no. 4, pp. 977–981, 2002. View at: Google Scholar
  201. Y. Seow and M. J. Wood, “Biological gene delivery vehicles: beyond viral vectors,” Molecular Therapy, vol. 17, no. 5, pp. 767–777, 2009. View at: Publisher Site | Google Scholar
  202. D. Ghosh, Y. Lee, S. Thomas et al., “M13-templated magnetic nanoparticles for targeted in vivo imaging of prostate cancer,” Nature Nanotechnology, vol. 7, no. 10, pp. 677–682, 2012. View at: Publisher Site | Google Scholar
  203. M. S. Muthu and B. Wilson, “Multifunctional radionanomedicine: a novel nanoplatform for cancer imaging and therapy,” Nanomedicine, vol. 5, no. 2, pp. 169–171, 2010. View at: Publisher Site | Google Scholar
  204. J. W. Bulte and M. Modo, Eds., Nanoparticles in Biomedical Imaging: Emerging Technologies and Applications, Springer, New York, NY, USA, 2007.
  205. D. Janczewski, Y. Zhang, G. K. Das et al., “Bimodal magnetic-fluorescent probes for bioimaging,” Microscopy Research and Technique, vol. 74, no. 7, pp. 563–576, 2011. View at: Publisher Site | Google Scholar
  206. P. A. Jarzyna, A. Gianella, T. Skajaa et al., “Multifunctional imaging nanoprobes,” Wiley Interdisciplinary Reviews, vol. 2, no. 2, pp. 138–150, 2010. View at: Publisher Site | Google Scholar
  207. “Nanoparticles in biomedical imaging, emerging technologies and applications,” in Fundamental Biomedical Technologies, M. M. J. M. Jeff and W. M. Bulte, Eds., vol. 102, Springer, New York, NY, USA, 2008. View at: Google Scholar
  208. M. T. McMahon, A. A. Gilad, M. A. DeLiso, S. M. Cromer Berman, J. W. M. Bulte, and P. C. M. Van Zijl, “New “multicolor” polypeptide diamagnetic chemical exchange saturation transfer (DIACEST) contrast agents for MRI,” Magnetic Resonance in Medicine, vol. 60, no. 4, pp. 803–812, 2008. View at: Publisher Site | Google Scholar
  209. H. Cabral, Y. Matsumoto, K. Mizuno et al., “Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size,” Nature Nanotechnology, vol. 6, no. 12, pp. 815–823, 2011. View at: Publisher Site | Google Scholar

Copyright © 2014 Su-Eon Jin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

5870 Views | 2105 Downloads | 49 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.